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Abstract 
 
(i) One of the key questions of cancer biology is whether the tumor development is caused by 
rare cancer stem cells. Evidence for this model and for the model of clonal evolution of 
tumorogenic clones are currently conflicting against each other. We show that both 
hypotheses can be true if one takes into account that tumors could arise from cells that are 
distinct from those which maintain the tumor. We have compared acute lymphoid and chronic 
myeloid leukemia and could observe that whereas myeloid leukemia develop from the same 
CSCs initially and during progression, lymphoid leukemia change the identity of CSCs that 
initiate to a distinct CSC that maintains the leukemia. This finding is essential in 
understanding of the process underlying leukemia development and explains the lineage 
determination so often associated with particular tumors. 
(ii) The BCR/ABL-oncogene activates many different pathways including Stat5-signaling. 
We show that Stat5 is required for the maintenance of leukemia progression. Deletion of Stat5 
in growing leukemia could completely ablate myeloid and a lymphoid leukemia. Stat5 is 
involved in survival of leukemic cells, since its deletion leads to a G0/G1 cell cycle arrest and 
subsequent apoptosis induction in imatinib-sensitive and in imatinib-resistant cells. Therefore, 
Stat5 is a potential drug for treatment of leukemia. 
(iii) We demonstrate an essential function of Stat5 in the EpoR/Jak2/Stat5 axis during 
erythropoietic development. We could show here that expression of Stat5 in Jak2- and EpoR-
deficient erythroid cells could rescue the erythropoiesis in vitro. Introduction of an 
constitutively active Stat5 mutant (cS5F) into Jak2-/- fetal liver cells, could rescue 
erythropoiesis and myelopoiesis in vivo. 
(iv) Contrary to the implicated role of Stat1 as tumor suppressor, we describe a tumor-
promoting role for Stat1 in MPD and lymphoid leukemia. Stat1-/- tumor cells express low 
levels of MCH class I molecules on their surface and therefore exert a better recognition and 
more efficient killing by NK-cells. We could also describe that Stat1-/- tumor cells acquire 
increased levels of MHC class I proteins, which could be a general mechanism of immune-
escape of hematopoietic tumors.  
(v) Finally, we demonstrate an essential role of Stat5 in lymphopoiesis and lymphoid 
leukemia. Stat5 is essential for the development of CD8+ T-cells, B-cells and gdT-cells. 
Because the B-cell development was impaired at the pre-pro B-cell stage, the initial 
transformation by Abelson oncogenes was completely abrogated in vitro and in vivo. This is 
the first description of Stat5 as a major player in normal hematopoiesis and malignancy. 
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Zusammenfassung 
 
(i) Eine der zentralsten Fragen der Krebsforschung lautet, ob die Entwicklung eines Tumors 
durch selten vorkommende Krebs-Stammzellen verursacht wird. Zurzeit herrscht Unklarheit 
darüber, ob dieses Modell oder das Modell der klonalen Evolution von Tumorzellen der 
Wahrheit entspricht. Hier zeigen wir, dass beide Hypothesen wahr sein können, wenn man in 
Betracht zieht, dass Tumorzellen, die den Tumor erhalten, unterschiedlich von denen sind, die 
ihn initiieren. Wir haben akute lymphoide und chronisch myeloide Leukämien verglichen und 
entdeckten, dass die Tumor-initiierende und die Tumor-erhaltende Krebs-Stammzelle in 
myeloiden Leukämien zur ein und derselben Zellart gehört. In lymphoiden Leukämien 
hingegen ändert sich die Identität der Tumor-initiierenden Zelle zu einer andreren Krebs-
Stammzelle, die den Tumor erhält. Dieser Befund ist essentiell, um den Mechanismus der 
Leukämie-Entwicklung zu verstehen und erklärt die Prävalenz der Onkogene für bestimmte 
hämatopoietische Linien. 
(ii) Das BCR/ABL Onkogen aktiviert viele verschiedene Signaltransduktionswege, u.a. auch 
den Stat5 Signalweg. Wir zeigen, dass Stat5 essentiell für die Erhaltung dieser Leukämie ist. 
Die Beseitigung von Stat5 in einer etablierten Leukämie konnte sowohl myeloide als auch 
lymphoide Leukämien heilen. Stat5 ist mitverantwortlich für das Überleben von 
leukämischen Zellen, da dessen Beseitigung zu einem G0/G1 Zellzyklus-Arrest und 
anschliessend zu Apoptose führt - sowohl in Imatinib-empfindlichen wie auch in Imatinib-
resistenten Zellen. Daher ist Stat5 ein potentieller Kandidat für neue Therapien. 
(iii) Wir zeigen eine essentielle Funktion von Stat5 in der EpoR/Jak2/Stat5-Achse in der 
erythroiden Entwicklung. Wir konnten zeigen, dass die Überexpression von Stat5 in Jak2- 
und EpoR-defizienten erythroiden Zellen die Erythropoiese in vitro retten kann. Das 
Einbringen einer konstitutiv-aktiven Stat5-Mutante (cS5F) in Jak2-/- foetalen Leberzellen 
konnte sowohl die Erythropoiese als auch die Myelopoiese retten. 
(iv) Im Gegensatz zu der erwarteten Rolle von Stat1 als Tumor-Suppressor, beschreiben wir 
eine Tumor-fördernde Rolle für Stat1 in MPD und lymphoider Leukämie. Stat1-/- Zellen 
exprimieren geringe Mengen an MHC Klasse I Molekülen an der Zelloberfläche und werden 
daher von NK-Zellen besser erkannt und eliminiert. Wir konnten weiters zeigen, dass Stat1-/-
Tumorzellen in der Lage waren, höhere MHC Klasse I Expression zu erlangen - was ein 
allgemeiner Mechanismus für das Entkommen hämatopoietischer Tumoren vor dem 
Immunsystem sein könnte. 
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(v) Wir zeigen eine essentielle Rolle für Stat5 in der lymphoiden Entwicklung und in 
lymphoider Leukämie. Stat5 ist erforderlich für die Entwicklung von CD8+ T-Zellen, von B-
Zellen und γδ T-Zellen. Aufgrund der Beeinträchtigung der B-Zell-Entwicklung im Pre-Pro-
B-Zellstadium, war die initiale Transformation mit Abelson-Onkogenen in vitro und in vivo 
völlig verhindert. Dies ist die erste Beschreibung von Stat5 als bedeutender Faktor in 
normaler Hämatopoiese und Leukämie. 
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1 Introduction 
 
1.1 Hematopoiesis and leukemia 
 
The developmental process of formation of all blood cells is called hematopoiesis. The word 
hematopoiesis is derived from greek words “haima” (blood) and “poiesis” (to make). Blood 
or the hematopoietic system is normally considered as an organ because of its complex 
structure. According to this, mature blood cells can be subdivided into three major cellular 
subpopulations. Erythrocytes or red blood cells are quantitatively the largest group of the 
hematopoietic system (4-6x106 cells/µl of human peripheral blood). The function of 
erythrocytes is the transport of oxygen to as well as the transport of CO2 from all organs in a 
body. The second largest population of the hematopoietic system is represented by 
thrombocytes or platelets (2-5x105 cells/µl), which are responsible for prevention of 
accidental, injury-induced blood-loss. The third category of blood cells is called leukocytes or 
white blood cells. Leukocytes are organized as distinct sub-populations, consisting of many 
different cell types, which are mainly involved in immune responses to viruses, bacterial 
pathogens and surveillance and eradication of evolving tumors. 
 
1.1.1 Origins of hematopoietic cells 
 
In all tissues, a cellular requirement for regeneration is needed, in order to supply the organ 
with all specific cells throughout lifetime. In the blood system, these cells are called 
hematopoietic stem cells (HSCs) and reside in the bone marrow (BM) of adult individuals 
(Weissman, 2000). 
However, despite blood being one of the best-studied organs, our knowledge about the 
earliest origins of blood cells is rather complex than clear. The reason for this is that 
development, per se, is a hierarchical system and therefore it assumes the existence of an 
ancestral cell for the whole blood system. Until now, emergence of hematopoietic cells has 
been described in four spatially and temporarily different sites of the embryonic development 
(Choi et al., 1998; Gekas et al., 2005; Muller et al., 1994; Samokhvalov et al., 2007). This 
chapter focuses on the description and explanation of these four origins of hematopoietic 
cells. 
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Figure 1: Spatial and temporal sites of origin of HSCs. 
Upper panel: Developmental timewindows for shifting sites of hematopoiesis. 
Lower panel: Hematopoiesis in each location favors the production of specific 
blood lineages. Abbreviations: ECs, endothelial cells; RBCs, red blood cells; 
LTHSC, long-term hematopoietic stem cell; ST-HSC, short-term hematopoietic 
stem cell; CMP, common myeloid progenitor; CLP, common lymphoid progenitor; 
MEP, megakaryocyte/erythroid progenitor; GMP, granulocyte/macrophage 
progenitor (adapted from Orkin and Zon, 2008) 
 
Interestingly, and common to all findings, one can conclude that the first commitment to the 
hematopoietic fate sets on in a part of the mesodermal germ layer called ventral mesoderm, 
right after the initiation of gastrulation (Murry and Keller, 2008). Temporarily, the 
development of blood cells can be subdivided in two major waves (Figure 1). In mice, the 
primitive erythropoiesis takes place from E7.25-E9.0 (Palis et al., 1999; Wong et al., 1986). 
The definitive erythropoiesis takes place from about E8.25-E10.5 and completely replaces the 
primitive erythropoiesis (Palis, 2008; Palis et al., 1999). Spatially, the onsets of primitive and 
definitive erythropoiesis are located in the yolk sac, but later on, the definitive erythropoiesis 
is relocated to the fetal liver. Upon the switch to fetal liver, the hematopoiesis converges to 
one organ in which the production of all mature lineages and amplification of hematopoietic 
cells takes place. 
 
1.1.1.1 Hemangioblast hypothesis 
 
Strikingly, during the stage of primitive erythropoiesis, primitive erythrocytes are present 
throughout the embryo proper already before the first emergence of HSCs. This finding 
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supports the (first of four) postulation of blood cell formation by a cell called hemangioblast. 
Due to the close spatial interaction between blood and endothelial cells in the yolk sac, it was 
hypothesized that a common ancestor (hemangioblast) could give rise to both, the 
hematopoietic and endothelial lineages during embryonic development (Figure 1, Ferkowicz 
and Yoder, 2005; Haar and Ackerman, 1971). Although, the experimental evidence for the 
existence of hemangioblast has been described in vitro (Choi et al., 1998) and in vivo (Huber 
et al., 2004), the formal proof of a single cell asymmetrically dividing into an erythroid and an 
endothelial cell, is still missing. The hemangioblast-hypothesis provides an explanation why 
primitive erythrocytes could be observed in embryos without the existence of a HSC, but does 
not explain how the emergence of HSCs is supported. 
 
1.1.1.2 The AGM-region 
 
The best established view of the place of origin of HSCs during embryonic development is 
the aorta-gonad-mesonephros (AGM) region. It consists of the dorsal aorta, the mesenchyme 
that engulfs the dorsal aorta and the urogenital ridges (Cumano et al., 1996; Ferkowicz and 
Yoder, 2005; Medvinsky and Dzierzak, 1996; Muller et al., 1994). It has been proposed that 
the cells residing in the ventral wall of dorsal aorta (hemogenic endothelial cells) are able to 
budd off HSCs (North et al., 1999; North et al., 2002). It should be mentioned here, that the 
identity of HSCs can only be assayed functionally and retrospectively by the observation of 
long-term engraftment and contribution to all hematopoietic lineages in animals transplanted 
with HSCs. Indeed, experimental evidence for AGM region as the source of HSCs was 
obtained by single cell transplantation studies of E11 AGM cell suspensions in primary and 
serially transplanted mice (Muller et al., 1994). 
 
1.1.1.3 Yolk sac 
 
In contrast to the AGM-region being the site of origin of HSCs, it has repeatedly been 
described that yolk sac might also be a place where HSCs are produced during embryonic 
development. Interestingly, early studies have shown that removal of yolk sac from E7.5 
embryos and further cultivation in vitro, yielded an ablation of all hematopoietic cells (Moore 
and Metcalf, 1970). A more recent work strengthens the theory of yolk sac origin of HSCs 
(Samokhvalov et al., 2007). Here, the use of a transgenic mouse that was able to induce lacZ 
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expression only in Runx1-positive cells enabled the scientists to follow the fate of yolk sac 
cells in vivo (Runx1 is exclusively expressed in the yolk sac at E7.5). Activation of lacZ at the 
day 7.5 of pregnancy was sufficient to permanently stain all hematopoietic cells. Since the 
AGM-region could be stained as well, it was concluded that the yolk sac rather than the 
AGM-region is the site of origin of HSCs. However, the Runx1+ cells described here could 
only constitute recipient mice if injected into the fetal liver of newborn mice - which indicated 
that further signals and maturation steps are required from the AGM-region or the fetal liver 
to obtain a full functioning HSC. This raises the possibility that these yolk sac cells might 
presumably be precursors of fetal HSCs. 
 
1.1.1.4 Placenta 
 
A very recent and intriguing observation suggests that HSC activity might also be initiated in 
the placenta of developing embryos (Rhodes et al., 2008). Interestingly, HSCs have been 
detected in placental tissue in several studies, but it has never been clear whether they are 
really generated there or whether placenta only provided the right microenvironmental cues 
for HSC expansion. To elucidate this, the authors have used mice which lack the heart beat 
and therefore no HSCs could be transported to placenta by the blood-circulation system 
(Koushik et al., 2001). Strikingly, mice lacking the Na+/Ca2+ transporter Ncx1 could develop 
Runx1+/CD41+ HSCs in the placenta. Additionally, Runx1+/CD41+ HSCs contributed to all 
hematopoietic lineages upon serial transplantation. 
 
1.1.2 Fetal and adult (bone marrow) hematopoiesis 
 
It is commonly accepted that the fetal liver is the site of expansion and differentiation of 
HSCs into all mature lineages. In addition, the fetal liver does not serve as the site of HSC-
generation but provides a niche for amplification of hematopoietic cells, in order to produce 
enough cells to colonize all lymphoid organs after birth (Orkin and Zon, 2008). Compared to 
adult HSCs, fetal liver HSCs are different in their homeostatic properties. Accordingly, fetal 
liver HSCs enter the cell cycle more often than BM HSCs (Bowie et al., 2006; Kim et al., 
2007). 
Common to fetal and adult hematopoiesis is the hierarchy of developmental stages and the 
ability to differentiate into erythroid, myeloid and lymphoid cells from a common ancestor 
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(HSC). During the past two decades our view of the hematopoietic development has 
strengthened mainly through the discovery and purification of distinct hematopoietic 
subpopulations by FACS-sorting using a combination of unique surface markers. This 
powerful method has enabled researchers to test every single hematopoietic stem and 
precursor cell population for their ability to differentiate into mature cells in vitro and in vivo. 
Hence, a rare population in the BM could be identified that was negative for the expression of 
all tested lineage markers (lin-) and that expressed early developmental markers c-kit 
(CD117; Stem cell factor SCF-receptor) and Sca-1 (Ikuta and Weissman, 1992; Spangrude et 
al., 1988). This population, termed as LSK (for lin-/Sca-1+/c-kit+), turned out to be enriched 
for HSCs and could be serially transplanted into lethally irradiated recipient mice with 
successful engraftment (Ikuta and Weissman, 1992). Studies with additional cell surface 
markers have revealed a further heterogeneity among the HSC-population and have led to the 
discrimination between long-term repopulating hematopoietic stem cells (LT-HSCs), short-
term repopulating hematopoietic stem cells (ST-HSCs) and multipotent progenitors (MPPs) 
(Osawa et al., 1996; Randall et al., 1996). However, the differences between the ST-HSCs 
and the MPPs turned out to be less prominent than expected. For instance, transplantation of 
ST-HSCs or MPPs into irradiated hosts has always led to a contribution to all three major 
blood lineages. The engraftment, however, was only temporarily and the differentiated cells 
have disappeared after 3-4 weeks - with ST-HSCs showing longer engraftment than MPPs 
(Morrison et al., 1997; Morrison and Weissman, 1994). Our classical view of the HSC-stages 
shows a linear connection between the LT-HSCs, ST-HSCs and MPPs. At the stage of MPPs, 
the hematopoietic development splits up for the first time into two branches - the common 
lymphoid progenitors (CLPs) (Kondo et al., 1997) and the common myeloid progenitors 
(CMPs) (Akashi et al., 2000). Both precursors are able to give arise to all downstream 
populations of the respective lineage, but they are not able to efficiently repopulate irradiated 
hosts. Interestingly, whereas CLPs can strictly differentiate into the lymphoid lineage (B-, T- 
and NK-cells), CMPs determine their fates into myeloid and erythroid lineages by first giving 
rise to either granulocyte-macrophage progenitors (GMPs) or erythrocyte-megakaryocyte 
progenitors (MEPs) (Traver et al., 2001). 
It is exactly this rigid classical model that has been challenged over the last few years, for the 
reason of several findings showing an unexpected heterogeneity among different 
hematopoietic populations (Figure 2). According to the classical model, MPPs can give arise 
to all three hematopoietic lineages and a lineage commitment is established later at the stages 
of CMPs and CLPs. However, several groups have shown that some lineages are more 
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prominently, or even exclusively, chosen downstream of MPPs. For instance, about 25% of 
the MPP-population expressing high levels of fms-like tyrosine kinase 3 (Flt3 or Flk2) 
Flt3high, has been shown to give arise to mere lymphoid and myeloid lineage (Adolfsson et al., 
2005) and was termed lymphoid-primed multipotent progenitor (LMPP). Although another 
study has shown that LMPPs still possess a low (less than 3%) megakaryocyte-erythrocyte 
(MegE) potential, this issue remains a point of debate. 
 
 
Figure 2: Road map of early hematopoiesis 
A, Model proposed by Kondo et al (1997) & Akashi et al (2000) 
B, Model proposed by Adolfsson et al (2005) 
C, Model proposed by Pronk et al (2007) 
D, Model proposed by Arinobu et al (2007) 
(adapted from C.Murre – Cell Stem Cell 2007) 
 
Another report also suggests a rather complex view of the hematopoietic development. Here, 
Pronk et al have assessed the differentiation potential of myeloid progenitors using CD150, 
CD105 (Endoglin) and CD41. Interestingly, they could show a novel hierarchy of progenitors 
with myeloid and erythroid potentials (Pronk et al., 2007). 
A complete novel approach was undertaken by the group of Connie Eaves which re-evaluated 
the hematopoietic tree using functional markers (Hoechst and Rhodamine stainings for drug-
resistance pumps expressed on HSCs) in order to define HSC-potential on a single cell level 
(Dykstra et al., 2007). By doing so, they could define four novel classes of HSCs according to 
their lineage determination ability (termed α, β, γ and δ). α cells had high self-renewal 
activity but were prone to differentiate into the myeloid lineage. β cells had similar self-
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renewal activity and a multipotent potential. γ and δ cells, however lacked the ability to self-
renew but γ cell displayed a robust myeloid and lymphoid potential, whereas δ cell only 
contributed to the lymphoid lineage. 
Finally, the group of Koichi Akashi favors the view that multipotent cells like MPPs might be 
initially primed into the myeloid/erythroid or lymphoid lineage, depending on the expressing 
of GATA1 or PU.1, respectively (Arinobu et al., 2007). This, so called priming, determines 
the specific lineage and could be a hint for further plasticity of HSCs. 
 
1.1.3 Leukemia 
 
The word leukemia is derived from the ancient greek words “leukos” (white) and “aima” 
(blood). It is usually used to describe the cancer of the blood system. On their clinical 
etiology, the leukemias are simply subdivided in chronic and acute leukemias. Leukemias 
implicate real hematological malignancies and are therefore separated from the more benign 
hematological neoplasms like myeloproliferative disorders. 
 
1.1.3.1 Myeloproliferative Disorders 
 
Myeloproliferative disorders or, sometimes termed, diseases (MPD), is a classification of 
diseases that rely on a hyperproliferation of blood cells of the erythroid/myeloid lineage in 
general. Since this classification is based on historical and clinical/morphological 
discrimination of hematological neoplasms rather than on molecular pattern, the term MPDs 
still remains less well defined than that of classical hematological malignancies (leukemias) 
(Levine and Gilliland, 2008). The most prominent difference to classical leukemia is that 
MPDs are initially benign, but mostly develop into malignant forms. The first definition of 
MPDs dates back to 1951, when William Dameshek discovered that polycythemia vera (PV), 
essential thrombocytosis (ET) and primitive or idiopathic myelofibrosis (MF) were closely 
related (Kralovics et al., 2005; Levine and Gilliland, 2008). Today, the category of MPDs is 
further subdivided into two major subgroups consisting of Philadelphia Chromosome (Ph) 
positive and Ph-negative diseases. The initially defined PV, ET and MF are termed Ph-
negative MPDs, whereas the chronic myelogenous (or myeloid) leukemia (CML) is viewed as 
Ph-positive MPDs (Kralovics et al., 2005; Levine and Gilliland, 2008). This is due to the fact 
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that CML normally exerts a milder phenotype than other “malignant” forms of leukemia, and 
has first to evolve into an acute phase disease. 
The recent discovery of a dominant mutation in the pseudokinase domain of Jak2 has 
revolutionized our view of MPDs, especially of the Ph-negative origin (James et al., 2005; 
Kralovics et al., 2005; Levine et al., 2005). A point mutation leading to a mis-translation of 
one amino acid (valine 617 to phenylalanine) was discovered to be the cause of 80% of PV, 
50% of MF and about 20% ET in human patients. Interestingly, all three forms lead to 
fibrosis of the BM and eventually cause death. The discovery of the Jak2V617F mutation was 
therefore a genetic or molecular proof for the common pathogenesis of PV, ET and MF. 
Due to historical/clinical and genetic/molecular reasons, CML is treated in this chapter as 
both a leukemia, and a MPD. Therefore it will be discussed in more detail in the next chapter 
(chronic leukemia). 
 
1.1.3.2 Chronic leukemia 
 
Chronic leukemias are characterized by their clinical etiology, which is described as a year-
long (=chronic) disease of the blood system. Normally, and inevitably, chronic leukemia, 
after an accelerated phase further proceeds into an acute phase. Chronic leukemia is 
characterized by extremely high numbers of relatively mature cells. It occurs predominantly 
in elder persons and is more easily treated due to reduced lethality rate. According to the cell 
lineage affected, chronic leukemia is further subdivided into a lymphoid and a myeloid form, 
CLL and CML, respectively. 
Chronic lymphocytic or lymphoid leukemia (CLL) mostly affects adults over the age of 55 
years and almost never occurs in children. CLL most often affects the B-lymphoid lineage 
and the survival rate is 77% after 5 years (Boelens et al., 2009; Chiorazzi et al., 2005). 
Chronic myelogenous or myeloid leukemia (CML) also affects older persons and rarely 
children. CML progresses form the chronic phase to the accelerated phase over a period of 
several years. The accelerated phase further inevitably progresses to the acute phase, which 
completely resembles an acute leukemia. Due to the treatment with the tyrosine kinase 
inhibitor Imatinib-mesylate, the prognosis of about 56% survival after 5 years has changed to 
about 90% survival upon treatment (Druker, 2008; Faderl et al., 1999). 
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1.1.3.3 Acute Leukemia 
 
Acute leukemias are generally considered to have a poor prognosis. Acute 
lymphoblastic/lymphoid leukemia (ALL) is the most common form of leukemia in children 
but it also occurs later in aged persons (Foon et al., 1980; Piccaluga et al., 2007). 
Acute myelogenous/myeloid leukemia (AML) has a relatively complicated etiology, which is 
classified by the French-American-British (FAB) or the World Health Organization (WHO) 
systems. This is because AML seems to arise from, or secondarily acquire, a load of 
mutations (Bennett et al., 1976). 
Both acute leukemia are associated rather poor prognosis, that is about zero percent survival 
without treatment and 20-50% survival upon treatment. The best prognosis is achieved in 
childhood ALL, because of bone marrow transplantation or stem cell transplantations have 
high rate of success in children. 
 
1.1.3.4 Philadelphia Chromosome-positive leukemia 
 
Philadelphia chromosome (Ph) was the first chromosomal translocation to be identified to 
encode a fusion-protein BCR/ABL, the major cause of several forms of leukemia. Leukemias 
characterized by a specific genetic abnormality, a t(9;22)(q34;q11) translocation, result from 
the formation of combined chromosome from chromosomes 9 and 22 (Groffen et al., 1984; 
Nowell and Hungerford, 1960). As a result of the translocation, a fusion gene product 
(BCR/ABL) is created, representing a constitutively active tyrosine kinase that lacks the 
regulatory domains of its full protein alias c-abl (Clark et al., 1988; Konopka and Witte, 1985; 
Rowley, 1973). The presence of the Ph is linked to three hematopoietic malignancies: CML, 
ALL and chronic neutrophilic leukemia (CNL) (Wong and Witte, 2001). Interestingly, 
whereas in CML, BCR/ABL is responsible for about 95% of all cases, only about 20-30% of 
adult ALL and 2-10% juvenile ALL patients possess the Ph-chromosome. CNL, however, is 
extremely rare and will not be discussed in more detail here.  
The molecular basis for the three diseases is given through the identification of three different 
ways or breakpoints to form a BCR/ABL fusion protein (Wong and Witte, 2001). All 
different breakpoints are in the BCR-gene, whereas the breakpoint of the c-ABL gene remains 
the same. Therefore, three proteins with different weights exist in the already mentioned 
leukemias. 
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This thesis will focus on the two most prominent ones: the smallest BCR/ABLp185 (185kDa) 
protein occurring in about 20-40% of all ALLs and the medium BCR/ABLp210 (210kDa) 
predominantly arising almost all cases of CML (Wong and Witte, 2001). 
 
1.2 Jak/Stat signaling and disease 
 
1.2.1 Overview of Jak/Stat signaling 
 
The Janus kinase (Jak) and signal transducer and activator of transcription (Stat) proteins are 
members of an evolutionary conserved signaling pathway. The Jak/Stat pathway is involved 
in the signal transduction of developmental, proliferative and survival signals from the 
environment to the nucleus of cells, where activation or repression of an appropriate 
repertoire of genes is initiated, leading to adequate responses to extracellular stimuli (Calo et 
al., 2003; Levy and Darnell, 2002; Murray, 1996). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Jak/Stat signaling cascade 
Upon ligand binding, receptor chains dimerize and activate Jaks. Jaks 
subsequently phosphorylate the receptor chain and thereafter, Stats, which 
bind to the receptor. Phosphorylated Stats dimerize and translocate to the 
nucleus. (adapted from Levy and Darnell, 2002) 
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The function of Jak/Stat pathway is mediated by the binding of an extracellular stimulating 
ligand to its cognate receptor which resides in the cytoplasmic membrane (Figure 3). The 
receptors of a non-classical tyrosine kinase family lack their own tyrosine kinase domain and 
are dependent on the physical interaction with Jak tyrosine kinases, bound to the intracellular 
domains of the receptor chains. Upon ligand binding, the receptor chains homo- and 
heterodimerize and bring the Jaks in a close vicinity to each other so that they can 
autophosphorylate themselves. The subsequent phosphorylation of tyrosine residues of the 
intracellular receptor domain is a prerequisite for binding of Stats to the receptors. In a similar 
way, Stats get phosphorylated and activated by Jaks, they homo- or heterodimerize and are 
translocated to the nucleus. Stats are genuine transcription factor and lead (in most cases) to 
an activation of specific target genes (Levy and Darnell, 2002). 
 
1.2.2 Jaks 
 
There have been four members of Jak proteins identified until now, termed Jak1, Jak2, Jak3 
and Tyk2. All Jaks are expressed in a variety of tissues and it has been assumed that their 
function is mostly non-redundant. Analysis of knockout mice and identification of 
homozygous mutation in humans has implicated Jak proteins in many fundamental cellular 
processes. For instance, Jak1 and Jak2 knockout mice displayed the most severe phenotype, 
leading to an early embryonic lethality (Neubauer et al., 1998; Parganas et al., 1998; Rodig et 
al., 1998). It is thought that the function of Jak1 and Jak2 is therefore closely connected to 
either embryonic development per se, or to an essential role in hematopoietic development 
since the lethality of knockout embryos was shown to coincide with the onset of fetal 
hematopoiesis. Interestingly, the most receptors involved in the function of hematopoietic 
cells like proliferation, differentiation and homing - that are represented by the gp130-family, 
common gamma, common beta chains and interferon receptors - signal through Jak1 and 
Jak2. Deletion of Jak3 in mice has led to a severe combined immuno-deficiency  (SCID) 
phenotype due to the lack of T- and NK-, but not B-cells (Nosaka et al., 1995; Thomis et al., 
1995). Additionally, homozygous mutation in humans have been discovered in Jak3, that also 
led to a lack of T-cells, and Tyk2, which displayed a Hyper-IgE syndrome with increased 
susceptibility to different microorganisms (Minegishi et al., 2006; Notarangelo et al., 2001). 
Accordingly, Tyk2 knockout mice exhibited impaired interferon-response that affected the 
viral (Karaghiosoff et al., 2000) and bacterial (Karaghiosoff et al., 2003) response to 
pathogens. 
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Figure 4: Common structure of Jaks (A) and Stats (B) (adapted from Schindler et al, 2007) 
 
The structure of Jaks is comprised of seven unique domain structures, termed Jak-homology 
domains (Figure 4, JH1-7). Functionally, JH7-4 encode the FERM-domain, which is 
responsible for the binding to the cognate receptor chain and resides in the N-terminal part of 
Jak proteins. The SH2-like domain is adjacent to the FERM-domain and is followed by two 
unique Jak kinase domains. Interestingly, one the most C-terminal kinase domain is 
functional in Jaks and the prior kinase doman is therefore termed pseudo-kinase domain 
(Levy and Darnell, 2002). Recently, a mutation in this pseudo kinase domain was discovered 
in Jak2, that is involved in myeloproliferative disorders by possibly rendering the protein 
constitutively active (James et al., 2005; Kralovics et al., 2005; Levine et al., 2005). 
 
1.2.3 Stats 
 
Stat molecules consist of seven members - Stat1 to Stat6, whereas Stat5 is encoded by two 
different genes, Stat5A and Stat5B. In contrast to Jaks, studies on Stats have revealed a more 
redundant roles for Stat protein, with the exception of Stat3 and Stat5 (O'Shea et al., 2002). 
Knockouts for Stat1 and Stat2, for example, have led to an overall normal phenotype in mice, 
with defects becoming prominent only after pathogenic challenge - due to an impaired 
interferon response (Durbin et al., 1996; Meraz et al., 1996; Park et al., 2000). In case of Stat4 
and Stat6, a role in T-cell polarity has become obvious that is responsible in the decision 
between the Th1 and Th2 differentiation and cytotoxic versus humoral immune responses. 
While Stat4 acts downstream of IL-12 signaling and therefore supports the differentiation into 
Th1 cells that mediate anti-pathogenic immunity (Wurster et al., 2000), Stat6 is responsible 
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for IL-4 and Il-13 signaling and Th2 polarity to viruses and helminthes (Wurster et al., 2000; 
Zhu et al., 2001), respectively. As elucidated by knockout studies in mice, the functions of 
Stat3 and Stat5 seem to be more redundant than of all other Stats. For instance, Stat3 deficient 
mice were embryonically lethal already at E6.5-7.5, probably due to a developmental defect 
leading to an impaired closure of the neural tube (Takeda et al., 1997). While mouse 
embryonic fibroblasts (MEFs) could be isolated and expanded in vitro form Stat3 deficient 
mice, it is still unclear whether Stat3 has an important role in other adult cells (O'Shea et al., 
2002). Studies with dominant negative Stat3 or knockdown studies have however proposed an 
essential role in many adult cells and tissues (O'Shea et al., 2002). Similarly, Stat5 has been 
shown to exhibit an essential role in hematopoiesis (Hoelbl et al., 2006; Teglund et al., 1998; 
Yao et al., 2006). Stat5 knockout mice die mostly in utero and/or perinatally, and we and 
others have shown that Stat5 has an essential function in erythrocytes, T- and B-lymphocytes 
(Grebien et al., 2008; Hoelbl et al., 2006; Kerenyi et al., 2008). 
The structure of Stats is well conserved throughout the seven members and evolutionary from 
D. melanoganster to humans (Figure 4). Presumably, Stats are derived from one Stat gene by 
gene duplication. The structure has been solved by christallography for Stat1, Stat3 and Stat4, 
except for their N-terminal parts and therefore mechanisms of DNA-binding and dimerization 
are quite well understood (Becker et al., 1998; Chen et al., 1998; Vinkemeier et al., 1998). 
The N-terminal part is thought to be involved in dimerization of inactive Stats and in nuclear 
import/export. At least for Stat5, this domain has also been shown to mediate oligomerization 
(tetramers) (Moriggl et al., 2005). The coiled-coil domain in its vicinity consists of several 
hydrophilic residues, probably implicated in binding of regulatory proteins. The DNA-
binding domain (DBD) adjacent to the coiled-coil domain enables the binding of Stats to their 
consensus sequences (ISRE and/or GAS) in the promotor regions of many genes. Followed 
by a linker that assures the appropriate distance to DBD, the SH2-domain is the most 
conserved Stat-sequence and responsible for homo- and heterodimerization. Directly behind 
it, the tyrosine residue is situated to avoid intramolecular self-dimerization. At the C-terminal 
end of Stat proteins, the transactivating domain (TAD) is the least conserverd part among 
Stats. It induces promotor clearance and transcription of target genes (O'Shea et al., 2002; 
Schindler et al., 2007). 
 
1.2.4 Jak/Stat signaling in normal hematopoiesis 
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Almost all processes involving two or more hematopoietic cells including 
development/differentiation, survival/cell death and homing/immunity are regulated by 
cytokines. Interestingly, cytokines like interleukins, interferons and other growth factors all 
signal through the Jak/Stat signaling pathway. Therefore Jaks and Stats have an indispensable 
role in hematopoiesis. As already mentioned, the knockout phenotypes in mice and other 
experiments have implicated Jaks and Stats in a variety of cellular functions.  
 
1.2.5 Jak/Stat signaling in leukemia 
 
The unique prevalence of Jak/Stat signaling pathway in hematopoiesis has implicated it in 
malignancies arising from blood cells. It is generally thought that aberrant signaling 
downstream of many cytokines important for self-renewal, proliferation or survival of blood 
cells might be involved in leukemia formation (O'Shea et al., 2002). Especially, 
hematopoietic stem cells, progenitors and other transit amplifying cells might harbor the 
potential to become malignant. 
We and others have therefore focused on the elucidation of Jak/Stat signaling components 
that might be required for tumor initiation or tumor maintenance - and this is also one of the 
major focuses of this thesis. 
Jak1 and Jak2, for example, have been implicated in leukemia development for a long period, 
not only because of their redundant roles in hematopoiesis. It has been proposed that Jak1 and 
Jak2 would promote leukemia formation (Vainchenker et al., 2008; Ward et al., 2000). 
Several groups have shown that Jak1 and Jak2 act downstream of fusion proteins and 
oncogenes (e.g. v-abl, BCR/ABL) that drive leukemia. Due to the lack of genetic models to 
address this issues (Jak1 and Jak2 knockouts are embryonically lethal), it has taken until the 
knockdown techniques have become available, to strengthen this hypothesis (Vainchenker et 
al., 2008). However, recently we could show that in case of Jak1 a tumor promoting role 
might not be correct at least for lymphoid leukemia (Sexl et al., 2003). Even on contrary, v-
abl transformed Jak1 deficient fetal livers gave rise to an increased number of clones in vitro 
and have worsen the outcome of disease when transplanted in vivo. 
Jak2’s role in tumor promotion has been better substantiated. Tel/Jak2 is an occasionally 
occurring fusion protein due to a chromosomal translocation in childhood T-ALL (Schwaller 
et al., 1998). A recently identified point mutation in Jak2 has also been implicated in 50-90% 
of cases of polychythemia vera (PV) (James et al., 2005; Kralovics et al., 2005; Levine et al., 
2005). In a study described in this thesis, we have addressed this question using Jak2-
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deficient fetal livers (FL). Infection of Jak2-/- FL with a constitutively active mutant of the 
downstream player Stat5 (cS5F) has rescued erythropoiesis and myelopoiesis in vivo, but was 
not sufficient to induce leukemia formation, indicating that additional signaling was required 
for downstream of Jak2 for myeloid leukemia formation (Grebien et al., 2008). 
Tyk2 has also been evaluated for its involvement in leukemia formation. Interestingly, we 
could show that loss of Tyk2 in a B-ALL model had no effect on the tumor cell per se, but 
nevertheless has accelerated tumor formation by impairing the NK-cell cytotoxicity and 
surveillance of tumors (Stoiber et al., 2004). 
Stat1 has previously been shown to be a tumor suppressor in many tumors, although its role in 
leukemia formation has not been assessed (Shankaran et al., 2001). Very recently, we could 
show using a B-ALL and a MPD model, that Stat1 promoted leukemia development and its 
loss rendered the mice less tumor prone due to low MHC class I expression on the surface of 
tumor cells. Interestingly, Stat1-/- tumor cells could up-regulate MHC class I expression in 
order to escape the immunesurveillance by NK-cells (Kovacic et al., 2006). 
In contrast to Stat1, Stat3 has initially been implicated in cancer formation as a proto-
oncogene (Bromberg et al., 1999). Accordingly, active (phosphorylated) Stat3 has also been 
found in many leukemia and lymphoma (Yu and Jove, 2004). Stat3 is the major component 
downstream of gp130 receptor family and is therefore thought to be involved in 
differentiation and fate decision processes dependent on cytokines like LIF, IL-6, IL-11, G-
CSF etc. and in inflammation processes (Yu and Jove, 2004). Although a genetic depletion of 
Stat3 has not yet been assessed in leukemia formation, experiments using RNA interference, 
antisense oligonucleotides or dominant negative versions of Stat3 have implicated this protein 
in tumorigenesis (Kisseleva et al., 2002; Levy and Darnell, 2002). 
The role of Stat5 in leukemia formation has been assessed by several groups. For example, a 
constitutively active version of Stat5B was generated by substituting the histidine 299 and the 
serine 711 with arginine and phenylalanine, respectively (Burchill et al., 2003). A transgenic 
mouse bearing this mutant (Stat5B-CA) under the control of the µ-enhancer (Eµ) showed 
increased numbers of pro-B, mature α/β and γ/δT and NK/T, but no leukemia formation. 
Conversely, knockout strategy has initially been used to generate a hypomorphic version of 
Stat5 lacking the N-terminal part (Sexl et al., 2000; Teglund et al., 1998). Unfortunately, the 
rest of the protein was still expressed - leading to a somewhat mild phenotype in these 
knockout mice. For example, the mice were overall healthy, developed normally and showed 
only a reduced but not impaired transformation ability leading to lymphoid and myeloid 
leukemia formation. Interestingly, using a complete knockout of both Stat5 genes, we could 
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recently clarify the role of Stat5 in hematopoiesis and lymphoid leukemia (Hoelbl et al., 
2006). Indeed, Stat5 knockout mice were embryonically and perinatally lethal, but fetal liver 
cells from rare survivors showed an impaired B and T-cell development and an inability of 
transformation with v-abl and BCR/ABLp185 in vitro, and impaired leukemia development in 
vivo. 
 
1.3 Cancer stem cell hypothesis 
 
1.3.1 Evidence for cancer stem cells 
 
There has been emerging evidence over the last decade about the interrelationship between 
normal stem cells and tumor cells being capable of formation and development of novel 
tumors. Particularly, hematological malignancies have been shown to arise from rare or at 
least infrequent tumor cells that can be successfully transplanted into recipient mice (Al-Hajj 
et al., 2003; Bonnet and Dick, 1997; Lapidot et al., 1994; Ricci-Vitiani et al., 2007; Singh et 
al., 2004). The very first report states a successful transplantation of a rare cell fraction 
isolated by FASC-sorting from human AML-patients into non-obese diabetis (NOD)/severe 
combined immunodeficient (SCID) mice (Bonnet and Dick, 1997; Lapidot et al., 1994). 
These cells, forth on termed “cancer stem cells” (CSCs), have become the basis of the later 
postulated “cancer stem cell hypothesis”. Importantly, it was not only frequency that has 
characterized a potential cancer stem cell. Moreover, on the top of the fact that CSC 
represented only 0.2-1% of all AML cells, it was the rest of the AML cells that were not able 
to grow in serial transplants (Bonnet and Dick, 1997). This experiment has clearly shown that 
the rare cells were somewhat superior to all other cells in their capacity to form novel tumors. 
Additionally, this finding has pointed out that cancers, like normal organs, could be 
hierarchically organized and possess stem cell-like cells within them. Most strikingly, the 
phenotype by which the presumable CSCs were isolated from AML-samples resembled the 
surface marker combinations used to identify and isolate HSCs previously (Thy1-, CD34+ and 
CD38-) (Bonnet and Dick, 1997). 
In recent years, CSCs have also been reported in the cancers of brain, breast and colon (Al-
Hajj et al., 2003; Ricci-Vitiani et al., 2007; Singh et al., 2004). Interestingly, the marker 
expression on most if not all of these CSCs resembled closely the phenotype of HSCs. For 
instance, the prospective breast CSCs turned out to be lin-CD24- and CD44+ (Al-Hajj et al., 
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2003). The presumable brain and colon CSCs, on the other hand, expressed a novel surface 
marker CD133 (prominin) which was found to be enriched in the CSC-fraction and also 
expressed of normal human HSCs (Ricci-Vitiani et al., 2007; Singh et al., 2004). 
 
1.3.2 A paradigm cancer stem cell model 
 
The hematopoietic system is one of the best studied and therefore best described organs in 
mammals. As mentioned previously, the blood system consists of a well-studied hierarchy of 
cells with largely known ancestors (like HSCs) and descendents. Moreover, a load of 
phenotypic markers, either as cell surface proteins or intracellular players are known that can 
distinguish between all the described subpopulations (Adams and Scadden, 2006). It is 
because of these hallmarks that the hematopoietic system is established as a paradigm model 
for studying the cancer stem cell hypothesis. Additionally, the blood system has also been a 
source of many mutations, chromosomal translocations and genetic aberrations that are 
associated with different diseases and malignancies (Caligiuri et al., 1997; Jordan, 2002). For 
that reason, it is thinkable that the CSC hypothesis will have to prove in all aspects of this 
model. 
CSCs of the hematopoietic origin are also called leukemic stem cells (LSCs). In this thesis, 
the term CSC is used in order to achieve a general point of view. 
 
1.3.3 The cell of origin of cancer 
 
The quest for the cell of origin of cancer has turned out to be the most problematic part, right 
form the beginning of the cancer stem cell hypothesis. The reason for that is obvious from 
lessons with patients treated from leukemia. Normally, patients with cancer are treated by 
chemotherapy and, more recently with specific inhibitory drugs i.e.- like in case of CML - 
with imatinib-mesylate. However, a cure from cancer is only rarely achieved and in most 
cases the disease develops again, even after several years of successful treatment (Kantarjian 
et al., 2002; Ottmann et al., 2002; Sawyers et al., 2002). According to the cancer stem cell 
hypothesis these observations can be explained by the fact that CSCs share all abilities of 
normal stem cells like self-renewal, the ability the differentiate into more mature cells, 
quiescence, longevity and the ability to “pump out” drugs. 
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Unfortunately, there are two possibilities how this stem cell state of CSCs can be explained: 
First, it is possible that CSCs are normal stem cells that have acquired mutations over time 
and become aberrant. This is plausible if one thinks about stem cells needing less mutations, 
because the program of self-renewal is already active, or about the cells living long enough to 
acquire the mutation. Secondly, it is thinkable that CSCs are progenitors or even mature cells 
that have regained the ability to self-renew (Figure 5, Passegue et al., 2003). 
 
 
 
Figure 5: Leukemic stem cells (LSCs) could originate from normal HSCs 
or from progenitors (adapted from Passegue et al, 2003) 
 
Several findings indicate that both scenarios are true and therefore the interpretation of the 
cancer stem cell model became even more complicated. As already mentioned, the studies on 
AML indicate that HSCs might have become aberrant and gave rise to CSCs. The same might 
be true for other tissues like colon, brain and the breast. However, numerous recent studies 
have implicated that leukemia-initiating cells from AML expressed either a predominantly 
mature myeloid phenotype or consisted of a myeloid progenitor population rather than of 
HSCs (Kelly et al., 2007; Krivtsov et al., 2006; Somervaille and Cleary, 2006). 
Furthermore, it has been suggested that chronic phase CML is initiated in HSCs, or 
presumably LT-HSCs, because the characteristic Ph-translocation can be detected in several 
hematopoietic lineages of the same patient (Holyoake et al., 1999; Takahashi et al., 1998). 
Although in multiple studies BCR/ABL-positive CML (BCR/ABLp210) seemed to originate 
in the HSC-fraction during the chronic phase (Hu et al., 2004; Huntly et al., 2004; Krause et 
al., 2006), a different study placed the acute phase disease CSCs into the fraction of 
 24 
progenitors (Jamieson et al., 2004). Another, perhaps aberrant, spontaneous JunB-/- CML-like 
leukemia was initiated from LT-HSCs (Passegue et al., 2004) and a BCR/ABLp210 Arf-/- 
leukemia was initiated from pre-B cells (Williams and Cancelas, 2006). Strikingly, one recent 
study has reported that 5-FU treatment of donor BM prior to infection with BCR/ABL 
induced CML in serial transplants, whereas direct infection with BCR/ABL without 5-FU 
treatment could redirect the disease into B-ALL lineage (Hu et al., 2004). Interestingly, all 
studies mentioned here using BCR/ABL BM transplantation used 5-FU treatment prior to 
infection. Therefore, it is possible that 5-FU treatment per se had an effect on the etiology of 
myeloid leukemia and may have pre-influenced its outcome. 
 
1.3.4 The frequency of cancer stem cells and the generality of cancer 
stem cell hypothesis 
 
Recently, several reports have raised the possibility that the frequency of CSCs in a tumor 
might actually be underscored (Kelly et al., 2007; Krivtsov et al., 2006; Quintana et al., 2008; 
Somervaille and Cleary, 2006). In transplantation experiments with different forms of 
leukemia and with solid cancers, it could be demonstrated that the number of CSCs relative to 
all other tumor cells is higher than initially suggested. Hence, the numbers were estimated 
between 15-50% of all cells and probably even extend to all tumor cells. 
 
 
Figure 6: Tumors could arise either according to the cancer stem cell 
hypothesis (A) or by clonal evolution  (B) or by a combination of both 
(C). (adapted from Adams et al, 2008) 
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The notion for these findings came from the consideration that the only ability of rare tumor 
cells to develop novel tumors might be a consequence of a lack of appropriate tumor 
microenvironment in NOD/SCID mice (Adams and Strasser, 2008; Kelly et al., 2007). In 
other words, the xenotransplantation experiments used to substantiate the cancer stem cell 
hypothesis seemed to have failed to provide all tumor cells with essential growth factors. 
These findings have challenged the cancer stem cell hypothesis insofar as they suggest that 
tumor growth might indeed be supported by clonally evolving cells - a model already 
proposed to exist for cancer cells (Figure 6). 
 
1.4 Potential targets for treatment of hematopoietic malignancies 
 
It is one of the major challenges in cancer biology to effectively treat cancers. As already 
mentioned before, current therapies mainly focus on the treatment of the bulk of cancer cells 
with diverse chemotherapeutical agents. Chemotherapy however is effective only on the 
majority of rapidly growing cells and has various side effects. Therefore, the patients are only 
exposed to chemotherapeutical agents for a relatively short period of time and the procedure 
has to be repeated several times. In recent years, many effective drugs were discovered that 
target mostly different tyrosine kinases, known to be expressed in cancers. One of this 
tyrosine kinase inhibitor, Imatinib-mesylate (Glivec, or STI571) was the first effective 
inhibitor used to combat CML and has revolutionized the therapy and the survival of patients 
with CML (Druker et al., 2001a; Druker et al., 2001b). However, the search for other 
inhibitors has turned out to be difficult and time-consuming, so that only few other tyrosine 
kinase inhibitors are in clinical use or in clinical trials. Another disadvantage of tyrosine 
kinase inhibitors like Imatinib-mesylate is that patients have to be treated a life-long, since 
Imatinib-mesylate only suppresses CML-progression, but does not completely eradicate the 
cells (Kantarjian et al., 2002; Ottmann et al., 2002; Sawyers et al., 2002). 
 
1.4.1 Jak2 and Stat5 
 
One focus of this thesis was to evaluate the possibility that Jak/Stat-signaling components 
may be potential targets for treatment of leukemia. As already mentioned, Jak/Stat proteins 
are implicated in essential hematopoietic processes and are therefore considered to be 
powerful new drug targets for treatment of leukemia. Jaks, for example, are already ideally 
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suited for drug development, because they are tyrosine kinases and many current strategies 
involve inhibition of this protein family by ATP-analogons, which specifically bind into the 
ATP-binding pocket of the kinase domain and thereby inhibits its function (Druker, 2008). 
On the other side, Stats are transcription factors (TFs) and currently there is lack of 
knowledge how to effectively target transcription factor, although some approaches are quite 
promising. For example, one could design drugs that specifically bind to the DBD of a TF and 
inhibit its binding to DNA. Another approaches would be to specifically inhibit either the 
phosphorylation or the subsequent dimerization of Stat molecules. Probably, in future years, 
there will exist a strategy to cope these problems (Druker, 2008). 
However, our very recent studies have implicated two Jak/Stat-siganaling molecules, namley 
Jak2 (Grebien et al., 2008) and Stat5 (Hoelbl et al., 2006) to be potential targets for the anti-
tumor therapy. 
 
1.4.2 Targeting of cancer stem cells 
 
A completely different approach for complete eradication of cancers was established through 
the postulation of the cancer stem cell hypothesis. The cancer stem cell hypothesis implies 
that only a minority of cancer cells is able to progress the tumor thereby providing an 
explanation for unsuccessful outcomes of the conventional chemotherapy. The reason for the 
relapse of tumors is the inability to hit rare CSCs, so the hypothesis (Adams and Strasser, 
2008; Passegue et al., 2003; Stubbs and Armstrong, 2007). However, the mechanistic reasons 
for this might be of various arts. Therefore, it is thinkable that the frequency of CSCs plays a 
major role in their targeting. On the other hand, it could also be the acquired or intrinsic 
ability of CSCs to self-renew or to overcome death signals induced by fate determinants. 
Additionally, it is possible that CSCs are more resistant to conventional drug therapy, because 
they could express “drug pumps”, similar to normal stem cells. 
Nevertheless, it is obvious that if the cancer stem cell hypothesis is correct, it will be 
necessary to identify the molecular means, which underlie these processes in order to 
eradicate all CSCs. Additionally, it will also be required to discover differences between the 
normal and cancerous stem cells, so that a therapy can be designed that specifically impairs 
CSCs but keeps the normal stem cells alive. 
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2 Aims of this study 
 
The main aim of this study was to elucidate the role of Jak/Stat-signaling components in 
normal hematopoiesis and leukemia. The immense importance of Jak/Stat signaling, as 
discussed in the introduction part of this thesis, and the availability of novel genetic tools (i.e. 
novel transgenic mouse models, discovery of new phenotypic markers and definition of more 
exact hematopoietic populations and new leukemia models) has made it necessary to newly 
address or to re-evaluate the function of Jak/Stat proteins in homeostasis and disease. The 
focus has been set on the evaluation of the janus kinase Jak2 and the transcription factors 
Stat1 and Stat5. 
Beside the role in normal hematopoiesis, we have addressed the question of the impact of 
these proteins for the initiation and maintenance of leukemia. Therefore, several models 
covering MPDs, lymphoid and myeloid, as well as acute and chronic leukemia, have been 
tested during the thesis work. As can be depicted from the results part, the major focus within 
this work was made on the transcription factor Stat5, mostly because of the discovery of its 
striking phenotype and involvement in several lineage decisions as well as leukemia 
formation. Moreover, this thesis has contributed to some essential findings concerning the 
role of Stat1 in leukemia progression and immune surveillance. 
Interestingly, while performing experiments in different leukemia models, we could also 
observe a link between the initiation and maintenance of leukemia, which had provided a 
foundation for a novel model about the development of leukemias in general. 
 
This thesis consists of five major parts: 
 
(i) Cancer stem cells of different developmental fates nourish acute and chronic leukemia. 
  (manuscript in preparation for submission) 
 
(ii) Stat5 is a signaling bottleneck for the maintenance of bcr/abl-positive leukemia. 
  (under revision in Cancer Cell since 2009 March 2nd) 
 
(iii) Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2 
(published in Blood. 2008 May 1;111(9):4511-22. Epub 2008 Jan 31) 
 
(iv) STAT1 acts as a tumor promoter for leukemia development. 
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(published in Cancer Cell. 2006 Jul;10(1):77-87) 
 
(v) Clarifying the role of Stat5 in lymphoid development and Abelson-induced 
transformation. 
(published in Blood. 2006 Jun 15;107(12):4898-906) 
 
Detailed aims and outcomes of the major thesis parts: 
 
(i) Cancer stem cells of different developmental fates nourish acute and chronic leukemia. 
 
Boris Kovacic, Andrea Hoelbl, Marc A. Kerenyi, Memetcan Alacakaptan, Gabriele Stengl 
and Hartmut Beug 
 
This manuscript describes the key question of cancer biology, which is whether the tumor 
development is caused by rare cancer stem cells. Evidence for this model and for the model of 
clonal evolution of tumorogenic clones are currently conflicting against each other. We show 
that both hypotheses can be true if one takes into account that tumors could arise from cells 
that are distinct from those which maintain the tumor. We have compared acute lymphoid and 
chronic myeloid leukemia and could observe that whereas myeloid leukemia develop from the 
same CSCs initially and during progression, lymphoid leukemia change the identity of CSCs 
that initiate to a distinct CSC that progresses the leukemia. This finding is essential in 
understanding of the process that underlies leukemic development and explains the lineage 
determination so often associated with particular tumors. 
 
(ii) Stat5 is a signaling bottleneck for the maintenance of bcr/abl-positive leukemia. 
 
Andrea Hoelbl, Christian Schuster, Boris Kovacic, Maria A. Hoelzl, Sabine Fajmann, Florian 
Grebien, Wolfgang Warsch, Gabriele Stengl, Lothar Hennighausen, Hartmut Beug, Richard 
Moriggl, Veronika Sexl. 
 
This study addresses for the first time the role of Stat5 protein in the maintenance of 
progressing leukemia. The BCR/ABL-oncogene was implicated in a plethora of different 
pathways and Stat5 has been suggested to mediate the most important downstream signals. 
Here we show that Stat5 is a suitable target for therapy because it is required for the 
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maintenance of leukemia progression. Deletion of Stat5 in growing leukemia in vivo could 
completely ablate the leukemic cells of a myeloid and a lymphoid leukemia. We further show 
that Stat5 seems to be involved in survival of leukemic cells, since its deletion leads to a 
G0/G1 cell cycle arrest and subsequent apoptosis induction in imatinib-sensitive and in 
imatinib-resistant cells. These results clearly demonstrate that Stat5 is a potential candidate 
for treatment of leukemia and could be used in addition to imatinib treatment. 
 
(iii) Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2 
 
Florian Grebien, Marc A. Kerenyi, Boris Kovacic, Thomas Kolbe, Verena Becker, Helmut 
Dolznig, Klaus Pfeffer, Ursula Klingmüller, Mathias Müller, Hartmut Beug, 
Ernst W. Müllner and Richard Moriggl 
 
This study demonstrates an essential function of Stat5 in the EpoR/Jak2/Stat5 axis for the 
induction and homeostasis of erythropoietic development. We could show here that 
expression of Stat5 in Jak2- and EpoR-deficient erythroid cells could rescue the 
erythropoiesis in vitro. By utilizing a constitutively active Stat5 mutant (cS5F) into Jak2-/- 
fetal liver cells, we could further show that cS5F could rescue erythropoiesis and 
myelopoiesis in vivo. Additionally, Jak2 was found to require c-kit-signaling through SCF 
and that SCF could induce Stat5 activity. 
 
(iv) STAT1 acts as a tumor promoter for leukemia development. 
 
Boris Kovacic, Dagmar Stoiber, Richard Moriggl, Eva Weisz, René G. Ott, Rita Kreibich, 
David E. Levy, Hartmut Beug, Michael Freissmuth and Veronika Sexl 
 
Stat1 has been considered a tumor suppressor as an immune regulator of the surveillance of 
tumors. In contrast to this, this study describes a tumor-promoting role for Stat1 in MPD and 
lymphoid leukemia models. The explanation for this observation is that Stat1-/- tumor cells 
express low levels of MCH class I molecules on their surface and therefore exert a better 
recognition and more efficient killing by NK-cells. We could also describe that Stat1-/- tumor 
cells acquire increased levels of MHC class I proteins as the tumor progresses. These findings 
collectively indicate that Stat1 is a tumor promoter in leukemia development and that the 
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upregulation of MHC class I is a general mechanism of immune-escape of hematopoietic 
tumors.  
 
(v) Clarifying the role of Stat5 in lymphoid development and Abelson-induced 
transformation. 
 
Andrea Hoelbl, Boris Kovacic, Marc A. Kerenyi, Olivia Simma, Wolfgang Warsch, 
Yongzhi Cui, Hartmut Beug, Lothar Hennighausen, Richard Moriggl, and Veronika Sexl 
 
This study demonstrates an essential role of Stat5 in lymphopoiesis and lymphoid leukemia. 
By comparing lymphoid cells from wildtype, Stat5dN/dN and Stat5-/- mice, we could 
demonstrate that Stat5 is essential for the development of CD8+ T-cells, B-cells and gdT-
cells. Interestingly, B-cell development was impaired at the pre-pro B-cell stage and therefore 
the initial transformation with the Abelson oncogenes was completely abrogated in vitro and 
in vivo. This publication is the first to implicate Stat5 as a major player in normal 
hematopoiesis and malignancy, because previous findings with Stat5dN/dN mice have 
exerted a rather mild phenotype. 
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3 Results 
 
3.1 Manuscripts 
 
3.1.1 Cancer stem cells of different developmental fates nourish acute 
and chronic leukemia 
 
Boris Kovacic1, Andrea Hoelbl1,2, Marc A. Kerenyi3, Memetcan Alacakaptan1, Gabriele 
Stengl1 and Hartmut Beug1 
 
1Research Institute of Molecular Pathology (IMP), 1030 Vienna, Austria 
2Institute of Pharmacology, Centre of Biomolecular Medicine and Pharmacology, Medical 
University of Vienna (MUV), 1090 Vienna, Austria 
3Max F. Perutz Laboratories, Department of Medical Biochemistry, Medical University of 
Vienna, 1030 Vienna, Austria 
 32 
Cancer stem cells of different developmental fates nourish acute and chronic leukemia 
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Stengl1 and Hartmut Beug1 
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Vienna, 1030 Vienna, Austria 
 
 
 
A key question in cancer biology is whether the processes of tumor-initiation and tumor-
progression are caused by rare cancer stem cells (CSCs). One widely accepted evidence 
for this model is that rare human cancer cells are able to reseed tumors in non-obese 
diabetic/ severe combined immunodeficient (NOD/SCID) mice1,2,3,4,5. However, the 
generality of this ‘cancer stem cell hypothesis’ has recently been questioned by several 
observations showing that a more frequent amount of tumor cells might represent 
CSCs6,7,8,9. Here we show that both scenarios are true if CSCs of distinct developmental 
stages initiate and maintain cancers. Acute lymphoid BCR/ABLp185 leukemia is 
initiated, but not maintained by the rare long-term hematopoietic stem cell population. 
Initiating-CSCs change their fate, are lost and the progressing tumor is maintained 
through frequent precursor B-cells. In contrast, the chronic myeloid BCR/ABLp210 
leukemia is both, initiated and maintained by rare malignant LT-HSCs. Our results 
indicate that lymphoid and myeloid tumors initially follow the cancer stem cell 
hypothesis, but lymphoid tumors progress by clonal evolution, whereas myeloid tumors 
progress according to the cancer stem cell model. This provides an explanation for the 
etiological discrepancy between the chronic and acute leukemia, and raises the question 
whether the mere targeting of rare CSCs might be successful for eradication of all 
tumors.  
 
The most important assumption of the cancer stem cell hypothesis is that tumors are 
hierarchically organized and supported by a rare population of cancer stem cells1,2,3,4,5. 
However, many acute-type tumors do not seem to be hierarchically organized but rather 
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consist of a homogenous population of tumor cells6,9,10,11,12. Hence, emerging evidence 
suggests that in some malignancies, tumor growth is supported by the majority of tumor cells. 
Apart from the question if the cancer stem cell hypothesis can be generalized to all tumors, it 
is also not clear whether the cancer stem cell, which initiates the tumor, and the cancer stem 
cell, which maintains the tumor, are one and the same cell. One possible explanation is that 
tumors develop and progress through a sequence of steps from a stem cell to a population of 
more mature tumor cells and that in some tumors, the initial cancer stem cell population is 
lost, whereas in others, it remains a part of the tumor13. In this case, tumors might undergo a 
process similar to normal tissue development and the existence of cancer stem cells might 
depend on a specific developmental stage and on the acquired oncogenic mutation. 
Whether some tumors are destined to develop into only one specific lineage, whereas others 
choose a distinct lineage or even multiple lineages, could therefore be dependent on both, the 
cell of origin and the oncogenic transformation event. A recent study, however, has 
implicated that 5-FU treatment of donor bone marrow prior to transplantation could influence 
the lineage decision of the normally CML-inducing BCR/ABLp210 protein. Without 5-FU 
pre-treatment, the transplanted mice developed a B-ALL14. However, most, if not all, studies 
of the cancer stem cell hypothesis involving BCR/ABL were performed using 5-FU pre-
treated bone marrow. Therefore, the degree to which the potential cancer stem cells might 
have been biased by the 5-FU treatment is rather unclear. 
In addition, the evidence that the genuine cancer stem cell population is uniquely responsible 
for the development of tumors and conversely, that eradication of cancer stem cells could 
destroy the tumor, is still lacking. 
To clarify whether tumors arise from rare cancer stem cells, we have compared the tumor 
etiology of two closely related oncogenes, BCR/ABL p210 and BCR/ABL p185. The product 
of the fusion oncogene BCR/ABL - generated by a chromosomal translocation t(9:22)15 and 
resulting in the Philadelphia chromosome (Ph)16,17 - is a constitutively active tyrosine 
kinase18, which empowers hematopoietic cells with proliferative and survival advantages. 
Interestingly, whereas exclusively in chronic myeloid leukemia (CML), the breakpoints of 
BCR and ABL generate a 210 kDa protein, a shorter version (185 kDa) exists in a fatal but 
rare childhood acute B-cell leukemia (B-ALL)19,20. Moreover, analysis of patients with CML 
has revealed that cells of all hematopoietic lineages are Ph+, suggesting that these 
translocations may arise in the HSC-compartment21,22. 
Accordingly, we have assumed that if BCR/ABLp210- and BCR/ABLp185-translocations 
originated in the HSC-compartment, transformation of either whole bone marrow (BM) or 
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LT-HSCs alone would lead to comparable frequencies and etiologies of leukemia in vivo. In 
contrast, transformation of whole BM would induce more frequent leukemia formation 
compared to LT-HSCs, if the both oncogenes transformed progenitor cells (figure 1A). We 
have infected BM and LT-HSCs (isolated from 5-FU untreated donors; see supplementary 
methods) with both oncogenes and injected them into lethally irradiated wildtype syngeneic 
mice (in order to keep an intact tumor microenvironment) but to avoid an interaction with the 
host immune system. All mice transplanted with BCR/ABLp210 developed a CML-like 
disease, whereas all mice bearing BCR/ABLp185 succumbed to a B-ALL (figure 1B). Both 
oncogenes have led to severe infiltrations of bone marrow (BM), spleen and liver in vivo 
(supplementary figure 1). Interestingly, the same results in terms of frequency and etiology of 
leukemia formation were obtained irrespectively of the population (whole BM versus LT-
HSCs) transformed by both oncogenes (figure 1B). These results clearly show that in both 
leukemias, the LT-HSC-population is capable of initiating tumor formation. 
However, even if originated in the most primitive hematopoietic cell, the fates of the two 
leukemias seem to be diametrically opposed. GFP+ BCR/ABLp210 leukemic cells were 
present throughout all lineages of the hematopoietic system (figure 2A and supplementary 
figure 2). In contrast, close analysis of GFP+ BCR/ABLp185 leukemic cells has revealed that 
they were almost exclusively composed of CD19+/B220+ precursor-B cells, except for a - 
somewhat aberrant - CD19+/Gr-1+ population in the BM (3.02%) of diseased mice. In case of 
whole BM-transformation, the clear discrepancy between BCR/ABLp210 and BCR/ABLp185 
leukemia could not be explained by the infection of different target cells, because in control 
mice, all mature hematopoietic lineages were GFP+ (figure 2A). Moreover, the transformation 
of mere LT-HSCs yielded the same results for both leukemias. Hence, we hypothesized that 
the most privileged population of BCR/ABLp185 leukemia must have had its origin in the 
LT-HSC. One possible explanation for this would be that BCR/ABLp185-oncogene forces 
the differentiation of LT-HSCs into the B-cell lineage. To understand how this process takes 
place, we have compared the HSC-compartment of BCR/ABLp185 with BCR/ABLp210 
terminally-diseased mice, both initially transplanted with transformed LT-HSCs. Strikingly, 
BCR/ABLp185 mice completely lacked leukemic GFP+ cells in the LT-HSC population 
(Figure 2B, 0% GFP+ cells) and also in more ST-HSC and MPP compartments 
(supplementary figure 2, 0% GFP+ cells within ST-HSC and MPP). This effect was even 
more evident in respect to the total numbers of leukemic, GFP+ HSCs in BCR/ABLp185 
leukemia - which were found ~ 10 fold reduced as compared to control animals (Figure 2C). 
In contrast, the leukemic HSC population was ~ 20 fold increased in BCR/ABLp210 
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leukemia (figure 2C and supplementary figure 2, 69.1% GFP+ cells in LT-HSC, 78.4% in ST-
HSC and 29% in MPP compartments). These results indicate that, even if originating in rare 
LT-HSCs, BCR/ABLp210 and BCR/ABLp185 leukemia both distinctly influence their fate. 
While BCR/ABLp210 highly augments the number of LT-HSCs and thereby increases the 
number and contribution to all progeny-lineages, BCR/ABLp185 seems to determine LT-
HSCs to one specific lineage and exhausts its pool. 
To confirm that BCR/ABLp185 LT-HSC indeed directly differentiate into more committed 
CD19+ cells in vivo, we have analyzed the fate of BCR/ABLp185- versus BCR/ABLp210-
infected LT-HSCs in vitro (figure 2D). BCR/ABLp185 LT-HSCs have differentiated into 
CD19+/B220+/IgM- precursor-B cells within 11-15 days (figure 2D, upper panel). In contrast 
to BCR/ABLp210+ LT-HSC, we could not detect any BCR/ABLp185 GFP+ HSC after 18 
days in culture (figure 2D, lower panel). Interestingly and in line with our findings, MOZ-
TIF2, a fusion protein also causing an acute form of leukemia (AML), could similarly 
transform HSCs and induce a mature myeloid leukemia in vivo23. 
So far, our data suggest that particular oncogenes might change the fate of the initial cancer 
stem cell and thereby direct the fate of a developing tumor. The cell in which the cancer is 
initiated (initiating-CSC) and the cell which maintains the tumor (preserving-CSC) might 
therefore be two developmentally different cells. Therefore, we have speculated whether the 
low and the high frequencies of CSC in some tumors would be a consequence of the 
developmental stage of preserving-CSC. To investigate this, we have modeled three scenarios 
in which CSCs represent different stem or fate-determined cell-stage of leukemia (figure 3A): 
The first assumption is that all tumor cells have the capacity to induce a novel tumor (Model 
1). The second possibility is that a rare stem cell population is exclusively capable to do so 
(Model 2). Conversly, the third possibility is that CSCs belong to a more mature progenitor 
cell pool (Model 3). 
To address this issues, we have purified BCR/ABLp210 or BCR/ABLp185 GFP+ LT-HSCs 
(lin-c-kit+Sca-1+Thy1lowFlt3-) from terminally diseased primary transplants by FACS sorting, 
mixed them with HSC-depleted wildtype BM and injected into lethally irradiated secondary 
recipients. Conversely, wildtype LT-HSCs were mixed with BCR/ABLp210 or 
BCR/ABLp185 GFP+ leukemic bone marrow cells which were devoid of all cells with HSC 
markers (see schemes in supplementary figure 3A and 3B). The expected results related to 
each one of the three models are summarized in figure 3A. Interestingly, when we 
transplanted GFP+LT-HSCs from the BCR/ABLp210 leukemic pool, we observed a fast 
disease onset (15±2 days) in 100% of mice analyzed (n=9). The disease was phenotypically 
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identical to the primary transplant and consisted of GFP+ cells in all hematopoietic lineages 
(figure 3B, upper panel). Moreover, leukemia development was not dependent on the cell 
dosage used for transplantation because injections of 100 - 70,000 cells did not significantly 
change the disease onset (data not shown). Strikingly, when we transplanted more mature 
BCR/ABLp210 leukemic cells (250,000 – 2,000.000) together with wildtype LT-HSC, we did 
not observe leukemia development in any transplanted animal over a period of 14 months 
(figure 3B, lower panel). 
In a clear discrepancy to this, transplantation of BCR/ABLp185 HSC-depleted leukemic cells 
combined with wildtype LT-HSCs yielded a fatal precursor B-cell leukemia in all mice 
observed within 14 days (n=8). This leukemia again consisted of a homogeneous 
CD19+/B220+/IgM- cell population, which infiltrated the BM, spleen, liver and peripheral 
blood of diseased mice (Figure 3C, lower panel, and supplementary figure 3C). Since no 
GFP+ BCR/ABLp185 LT-HSC were present at the time point of terminal disease (figure 2B), 
we decided to inject GFP- LT-HSCs, in case that some cells have down-regulated GFP 
expression but still might induce leukemia upon transplantation. Nevertheless, those cells did 
not induce leukemia in secondary recipients over a period of 8 months (Figure 3C, upper 
panel).  
These data clearly show that in progressing BCR/ABLp210 and BCR/ABLp185 leukemias, 
the diseases are maintained by CSCs that differ in their developmental fate - LT-HSCs and 
precursor B-cells, respectively. Normal precursor B-cells are lineage-restricted, whereas LT-
HSCs possess the unique ability to self-renew and to differentiate into all mature 
hematopoietic cells. Lacking any cellular models to address the molecular mechanisms of 
leukemogenicity on stem cells, we have put in efforts to cultivate BCR/ABLp210 and 
BCR/ABLp185 CSCs in vitro and to examine whether they share any properties with normal 
LT-HSCs. Therefore, we have FACS sorted BCR/ABLp210 LT-HSCs and BCR/ABLp185 
precursor B-cells from diseased mice and observed the outgrowth of leukemic cells under cell 
culture conditions. BCR/ABLp185 preserving-CSCs grew out rapidly in vitro using normal 
serum conditions (10% FCS). They were able to induce leukemia formation upon serial 
transplantation, but did not change their precursor B-cell phenotype nor did they express 
HSC-surface markers in vivo or in vitro (supplementary figure 4). BCR/ABLp210 CSCs, 
however, could not be grown under serum conditions (data not shown). This prompted us to 
cultivate the cells under serum-free conditions with defined growth factors enabling the 
proliferation of hematopoietic stem cells (SCF/Tpo/IGF-II and FGF-1). Interestingly, under 
these ‘self-renewal conditions’, proliferation of BCR/ABLp210 LT-HSCs was only achieved 
 37 
if cells were seeded at very low density. On the morphological level, the colonies consisted of 
a population of more adherent and a population of more suspended cells, both compiling 
“cobblestone-like” structures on dishes (figure 4A). Interestingly, efficient replating required 
FACS-sorting of forward scatter (FSC) high (large) cells (Figure 4A), whereas FSC low 
(small) BCR/ABLp210 LT-HSCs were unable to give rise to any colonies in vitro (movie 1 
and movie 2). In contrast to wildtype LT-HSC, which proliferated only for about 14 days, 
BCR/ABLp210 LT-HSCs could be expanded indefinitely (Figure 4B). In addition to this, we 
could observe expression of many classical HSC and HSC-niche markers (Table2).  
Strikingly, when we injected BCR/ABLp210 LT-HSCs, grown under self-renewal conditions, 
into lethally irradiated mice, we could induce a CML-like leukemia formation. The disease 
accompanied with an increase in GFP+ GR-1+/Mac-1+ cells and a contribution to CD19+ and 
CD3+ cells (figure 4C), indicating that these preserving-CSCs were able to differentiate in 
vivo. 
These results indicate that BCR/ABLp210 LT-HSCs possess all hallmarks of hematopoietic 
stem cells - including HSC marker surface expression, infinite self-renewal and 
differentiation into all mature lineages of the hematopoietic system - and of CSCs - like 
recapitulation of the tumor phenotype upon serial transplantation. In contrast, BCR/ABLp185 
CSCs are homogeneous precursor B-cells, do not express HSC surface markers and do not 
differentiate into mature B-cells in vivo or in vitro, but however they are able to reinitiate an 
acute leukemia in secondary transplants.  
One prediction of the cancer stem cell hypothesis is that rare cancer stem cells might be more 
resistant to chemotherapy than frequent mature cancer cells, because of drug-resistance 
transporters, which are expressed on normal tissue stem cells. Therefore, we have analyzed 
the possibility that BCR/ABLp210 LT-HSC would be more resistant to Imatinib-mesylate 
treatment than BCR/ABLp185 precursor-B cells. As indicated in figure 3E, BCR/ABLp210 
LT-HSC were indeed resistant to different concentrations of imatinib-mesylate, whereas 
BCR/ABLp185 precursor-B cells regressed in proliferation and cell number (figure 4D).  
However, knowing that BCR/ABLp210 CSCs possess all characteristics of LT-HSCs, one 
possible strategy to eradicate CSCs - even if they are insensitive to imatinib-mesylate 
treatment - would be to force them into lineage-commitment. As depicted in Figure 4F 
(middle panel), addition for cytokines for terminal differentiation into erythroid, myeloid and 
lymphoid lineages has completely changed the phenotype of BCR/ABLp210 CSC in vitro. 
After 7 days, the cultures consisted of a mixture of CD19+, Mac-1+ and CD71+/TER119low 
cells (figure 4F, upper panel and data not shown). To elucidate if those differentiated cells 
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were able to initiate leukemia in serial transplants, we have injected 250,000 cells together 
with 250,000 HSC-depleted BM cells into sub-lethally irradiated mice. None of the 
transplanted mice has developed leukemia or hyperplasia after a period of 12 months and 
close analysis of BM, spleens and blood has revealed that no GFP+ cells have emerged during 
the observed period (figure 4F, lower panel). 
 
The “cancer stem cell hypothesis” has been challenged by some observations showing a 
majority of tumor cells being responsible for tumor outgrowth. Our data unify and consolidate 
both theories by demonstrating that cancer stem cells have distinct developmental fates in 
terms of initiation and progression. In other words, these data suggest that oncogenes might 
endow cells with self-renewal and survival abilities only at specific commitment stages. In 
line with this are numerous studies showing that in acute leukemia, committed progenitors 
rather than HSCs could re-induce the disease upon serial transplantation6,24,10,11,12,25,24. Beside 
this, it might also be provocative to think that some CSCs are rare and others frequent as a 
consequence of abundance in the hematopoietic system. The goal of cancer therapy is the 
eradiction of all CSCs and therefore alternative targets are required for their efficient 
depletion. Interestingly, we found that BCR/ABLp210 CSCs were more drug-resistant to 
imatinib-mesylate treatment than BCR/ABLp185 CSCs. Therefore, the anti-cancer drug 
therapies in CML patients may be insufficient in eradication of chronic disease CSCs, but 
more efficient in killing of acute phase CSCs. However, the reason why chronic phase 
patients have unequally better prognosis than patients with acute form of leukemia might be 
due to the enormous total number of CSCs in acute leukemia. 
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Methods summary 
 
Mice 
All mice were kept under sterile conditions in individually ventilated IVC-cages at the IMP-
animal facility. Animal experiments were preformed and protocoled according to the rules of 
the Austrain Tierversuchgesetz 1988, licence no. MA58/1253/03 and MA58/001489/2008/12. 
Since STAT5fl/fl and Mx-1Cre mice had a mixed (C57Bl/6J and 129/Sv) background, all 
wildtype donor and recipient mice were obtained from F1 crosses of C57Bl/6J x 129/Sv 
(B6/129 F1) mice.  
 
Preparation of BM, spleens and PB 
Femurs and tibiae were cut at the ends and the bone marrow cells flushed using a 22-gauche 
needle with 1x PBS. Spleens were crushed with a plunger of a syringe through a 70µm cell 
strainer. Peripheral blood erythrocytes were lyzed in 1xEry-Lysis buffer. All cells were 
collected by centrifugation and resuspended in 1xPBS. 
 
Statistical analysis 
Statistics have been performed using paired and unpaired student’s t-test. 
 
Methods 
 
BM preparation and transplantation 
Four-to-six-week wildtype or STAT5fl/fl Mx1Cre mice were used as donors for six-to-eight-
week old recipient mice. No 5-FU treatments were performed in any of the transplant 
experiments to avoid a bias to the myeloid lineage or a depletion of the potential cell of origin 
of cancer. BM from donor mice was flushed from the femurs and tibiae, pooled and filtrated. 
Whole BM (2-2.5x106 cells/ml) was infected using stable producer lines carrying empty-
IRES-GFP, BCR/ABLp210-IRES-GFP, BCR/ABLp185-IRES-GFP as described earlier26.The 
stable producer cells (GP+E86 cell lines) were initially derived from mouse embryonic 
fibroblasts (MEFs) and display a supportive microenvironment/niche for hematopoietic cells 
and ES cells. 2-3x106 infected total BM cells were injected via tail-vein per lethally (10 Gy) 
irradiated B6/129F1 mouse. For LT-HSCs infections, the LT-HSCs were FACS-sorted as 
described later and infected with the mentioned producer cell lines on 96-well-plates in 
analogous way to whole BM26. For secondary transplantation, wildtype or GFP+ leukemic 
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LT-HSCs and HSC-depleted wildtype or GFP+ leukemic BM was FASC-sorted from sick 
primary transplanted mouse, mixed in the described manner (figure 3A) and injected into 
lethally irradiated secondary B6/129F1 recipients. To avoid differences in leukemogenicity of 
the sorted leukemic cells, we have waited until every single primary and secondary 
transplanted mouse has become terminally diseased. Similarly, mice that did not become sick 
in the expected latency time were observed over a period of at least 12 months before 
sacrificed. 
 
FACS analysis and sorting 
BM, spleen, liver and peripheral blood were isolated from every single transplanted mouse 
and the cells incubated with fluorescence-conjugated lineage antibodies (TER119, CD3, Mac-
1, Gr-1 and CD19). BM and spleens were also stained with CD71 and Ter119 antibodies to 
determine erythroid precursor cells. In addition, BM was stained with (1) lineage markers, c-
kit, Sca-1, Flt3 and Thy1.2 (or CD150) for detection of all HSC subpopulations, (2) with 
lineage markers, c-kit, Sca-1 and IL7Rα for detection of lymphoid precursors and (3) with 
lineage markers with IL7Rα, c-kit, Sca-1, CD16/CD32 and CD34 - for detection of myeloid 
precursor cells. Flow cytometric analysis of all organs was performed on 6-color BD FASC 
Canto (BD Biosciences) equipped with 488nm and 633nm lasers. 
FACS-sorting of wildtype and leukemic LT-HSCs as well as wildtype and leukemic HSC-
depleted BM was performed on 4°C immediately after biopsy of the diseased mouse and 
staining of BM cells with the mentioned HSC-markers using an 8-color BD FACS Aria 
equipped with 488nm, 633nm and 407nm lasers. 
 
Antibodies 
Lineage panel Kit containing biotinylated Ter119 (Ly-76, Ter119), CD3e (CD3ε, 145-2C11), 
CD45R/B220 (RA3-6B2), CD11b (Mac-1, M1/70) and Ly6G/Ly6C (Gr-1, RB6-8C5) were 
purchased from BD Pharmingen and eBioscience. Second step detection Streptavidin-APC-
Cy7, Ter119 (Ly-76, Ter119)-PE and -APC, CD135 (Flk-2/Flt3/Ly-72, A2F10.1)-PE, Flk-1 
(VEGF-R2/Ly-73, Avas12α1)-PE, CD3e (145-2C11)-PerCP, CD19 (1D3)-APC-Cy7, 
CD90.2 (Thy1.2, 53-2.1)-APC, Ly6G/Ly6C (Gr-1, RB6-8C5)-APC, CD62E (E-
Selectin/ELAM-1, 10E9.6)-PE, CD44 (Pgp-1/Ly-24, IM7)-PE, CD34 (RAM34)-APC, IgM 
(II/41)-APC, Ly6A/E (Sca-1, D7)-PE-Cy7, CD71 (Transferrin receptor, C2)-PE, CD16/CD32 
(FcgIII/IIR, 2.4G2)-PE, CD144 (VE-Cadherin, 11D4.1)-PE, CD162 (PSGL-1, 2PH1)-PE and 
CD31 (PECAM-1, MEC13.3)-PE were all obtained from BD Pharmingen. CD11b (Mac-1, 
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M1/70)-PE-Cy7, Tie-2 (Tek/CD202, TEK4)-PE, CD127 (IL7Ra, A7R34)-bio and CD117 (c-
kit, 2B8)-PE-Cy5 were purchased from eBioscience. CD150 (SLAMf1, TC15-12F12.2)-APC 
and CD127 (IL7Ra, SB/199)-PE were purchased from Biolegend. Hamster anti-mouse Notch-
1 (8G10) was purchased from AbD Serotec, rabbit anti-mouse Jagged-1 (H66) from Santa 
Cruz, APC-goat anti-rabbit IgG from Invitrogen and PE-goat anti hamster IgG from Acris. 
 
In vitro cultivation and differentiation 
Freshly sorted GFP+ LT-HSC population from BCR/ABLp210 diseased mice was cultivated 
in 4-wells (1000 cells/well) in serum-free medium (StemPro-34 SFM, GIBCO) containing 
Nutrient supplement (GIBCO), 2mM L-glutamine, Pen/Strep and supplemented with 10ng/ml 
mSCF, 20ng/ml mTPO, 20ng/ml IGF-II, 10ng/ml hFGF-1 (acidic) and 10ng/ml Heparin. 
Confluent outgrowth of “cobblestone”-like structures (figure 4A and movie 1) was obtained 
after about 6-7 days. Thereafter, the smaller cells growing on top of the more adherent ones 
were removed from the 4-well, the adherent rest was washed with 1xPBS, trypsinized and 
pooled together with the smaller cells. The cells were sorted in a FSChigh and a FSClow fraction 
and seeded at a density of 1000 cells per 6cm dish. This procedure of FSChigh/low sorting was 
repeated when the cells were confluent again. The dish dimensions could be increased at 
every sorting/replating step. 
 
Microscopy 
Live cell imaging of leukemic LT-HSCs was performed using a ZEISS Axiovert 200M Life 
Cell Observer with incubator. Before and during live observation, the cells were grown on 4-
well Lab-Tek Chamber Slides (Nunc). The data was analyzed using Metamorph software 
(Zeiss). 
Confocal microscopy was performed on a LSM 510 Meta/Axiovert 200M system from Zeiss. 
The cells were grown on 4-well Lab-Tek Chamber Slides, fixed and stained according to a 
previously described protocol and mounted in Vecta Shield with DAPI. 
 
Imatinib-mesylate treatment 
BCR/ABLp210 LT-HSC and BCR/ABLp185 precursor-B cells were plated at a density of 
30,000 cells on 96-wells in 100 µl medium supplemented with either no imatinib-mesylate, 
100µM imatinib-mesylate or 200µM imatinib-mesylate. On day 16, the cells were taken from 
wells and counted. 
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Figure legends 
 
Figure 1 | LT-HSCs are initiating-CSCs for BCR/ABLp210 and BCR/ABLp185 
leukemia, but BCR/ABLp185 CSCs change their fate during disease progression. 
A, Schematic overview of the hierarchical hematopoietic lineage. Potential initiating-CSCs 
are indicated by arrows. B, Either whole BM cells or FACS-sorted LT-HSCs alone were 
transduced with retroviruses encoding BCR/ABLp210, BCR/ABLp185 or an empty GFP-
labeled vector. All (13/13) BCR/ABLp210-transplanted mice developed a CML and all (6/6) 
BCR/ABLp185-transplanted mice developed a B-ALL, irrespective whether whole BM or 
purified LT-HSCs alone were initially used for transformation (see also supplementary figure 
1A). 
 
Figure 2 | BCR/ABLp185 CSCs change their fate during disease progression and are 
lost. 
A, FACS-analysis of peripheral blood cells isolated from control and terminally-diseased 
mice induced by transplantation of whole BM. Empty vector and BCR/ABLp210 leukemia 
prominently contribute to myeloid (Gr-1+/Mac-1+), lymphoid (CD19+ and CD3+) and 
erythroid (Ter119+) lineages, whereas BCR/ABLp185 mainly contribute to the B-lymphoid 
lineage. The indicated percentages represent relative amounts of GFP+ cells from each 
population analyzed (A and B). B, FACS-analysis of BM cells from control and terminally-
diseased mice induced by transplantation of LT-HSCs alone. In contrast to control or 
BCR/ABLp210 leukemic BM, BCR/ABLp185-diseased BM completely lacks GFP+ LT-
HSCs. C, Quantitative analysis of leukemic GFP+ HSC cells in all diseased and control 
groups. The total numbers of GFP+ cells per 100,000 BM cells and the fold-increase 
compared to empty vector-transplanted mice are indicated. The values for total GFP+ cell 
numbers are represented as means ± SED. D, Analysis of in vitro cell outgrowth by the 
transformation of LT-HSCs with BCR/ABLp210 and BCR/ABLp185, respectively. Contour 
blots indicate the lineage into which the cells have differentiated (upper panel) and the 
presence of HSCs (lower panel). For detailed information on in vitro cultivation see 
supplementary method section. 
 
Figure 3 | BCR/ABLp210 and BCR/ABLp185 preserving-CSCs are distinct in frequency 
and fate. 
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A, Models for disease-maintenance from differently committed preserving-CSCs. In model 1, 
all leukemic cell have the ability to re-initiate leukemia. Model 2 assumes that leukemia is 
maintained by frequent progenitor or lineage-restricted precursor cells and in model 3, the 
leukemia preserving cell is the rare LT-HSC. The predicted outcomes for transplantation of 
either the mixture of leukemic LT-HSCs with wildtype HSC-depleted BM or the mixture of 
wildtype LT-HSC with leukemic HSC-depleted BM, are indicated for every model. B, 
Preserving-CSCs from BCR/ABLp210 leukemia behave according to the model 3. Mixture of 
leukemic BCR/ABLp210 LT-HSCs with wildtype HSC-depleted BM induces a CML-like 
disease formation (upper panel) in 9/9 serially transplanted mice. Transplantation of the 
mixture of wildtype LT-HSCs with frequent, leukemic BCR/ABLp210 HSC-depleted BM 
leaves the mice disease-free for 14 months. No GFP+ cells are detectable after the observed 
period in the BM of 12/12 mice (lower panel). C, Preserving-CSCs from BCR/ABLp185 
leukemia behave according to the model 2. Mixture of all BCR/ABLp185 LT-HSCs with 
wildtype HSC-depleted BM prevents B-ALL formation in 4/4 serially transplanted mice 
(upper panel). Transplantation of the mixture of wildtype LT-HSCs with frequent, leukemic 
BCR/ABLp185 HSC-depleted BM induces a B-ALL formation (lower panel) in 8/8 serially 
transplanted mice. GFP+ leukemic cells in secondary transplanted mice exclusively comprise 
of precursor B-cells (lower panel). 
 
Figure 4 | BCR/ABLp210 preserving-CSCs keep all properties of stem cells in vitro. 
A, Scheme: Leukemic BCR/ABLp210 LT-HSCs were isolated from terminally-diseased 
primary transplanted mice and cultivated under conditions allowing for self-renewal of 
normal HSCs (see method section). The morphologically different cells were FACS-sorted in 
forward scatter high (FSChigh) and forward scatter low (FSClow) cells. Only FSChigh cells give 
arise to new colonies in vitro. The cells are injected into recipient mice under self-renewing or 
fate-determining conditions (subfigures C and F). B, growth curves representing the 
cumulative cell number of BCR/ABLp210 LT-HSC and wildtype LT-HSCs. BCR/ABLp210 
LT-HSCs grew continuously for at least 68 days. C, BCR/ABLp210 LT-HSCs under self-
renewing conditions were injected into recipient mice. FACS-blots indicate the contribution 
of BCR/ABLp210 LT-HSC to myeloid and lymphoid lineages. Induction of leukemia was 
observed in 3/3 mice. D and E, Imatinib-mesylate treatment of BCR/ABLp185 precursor B-
cells (D) and BCR/ABLp210 LT-HSCs (E). BCR/ABLp185 CSCs react with growth 
inhibition and decreased cell number whereas BCR/ABLp210 LT-HSCs do not. F, Enforced 
in vitro differentiation of BCR/ABLp210 LT-HSCs into mature cells and subsequent injection 
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into sublethally irradiated mice. FACS blots in upper panel show that the cells are already 
lineage-restricted at the time point of injection. Analysis of mice indicate no contribution to 
myeloid and lymphoid lineages (lower panel). No leukemia formation was observed.  
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Supplementary figure legends 
 
Supplementary figure 1 | All mice transplanted with BCR/ABLp210 developed a CML-
like disease, whereas all mice bearing BCR/ABLp185 succumbed to a B-ALL. 
A and B, Hematoxilin/eosine (H&E) staining of livers (A) and spleens (B) from diseased 
BCR/ABLp210 and BCR/ABLp185 mice. BCR/ABLp210-induced leukemia is a CML 
disease defined by predominant infiltration of relatively large myeloid blast cells and 
monocytes. BCR/ABLp185-induced leukemia is enriched with lymphoid leukemic cells 
indicated by a stronger hematoxiline stain and less prominent cytoplasma. 
 
Supplementary figure 2 | BCR/ABLp185 diseased mice completely lack leukemic cells in 
the ST-HSC and MPP-fractions. 
FACS-analysis of the BM isolated from control and terminally-diseased mice induced by 
transplantation of LT-HSCs alone. In contrast to empty vector and BCR/ABLp210 leukemic 
BM, BCR/ABLp185-diseased BM completely lacks GFP+ ST-HSCs and MPPs. One 
representative BM analysis from a control, a BCR/ABLp210 and a BCR/ABLp185-diseased 
mouse is shown. 
 
Supplementary figure 3 | BCR/ABLp210 and BCR/ABLp185 preserving-CSCs are 
distinct in frequency and fate. 
Scheme of all experiments performed with BCR/ABLp210 (A) and BCR/ABLp185 (B) 
preserving-CSCs. Presumable preserving-CSCs (either LT-HSCs or HSC-depleted leukemic 
pools) were FACS-sorted from every single primary diseased mouse and transplanted into 
secondary recipient mice The numbers of mice used for secondary transplantation per primary 
diseased mouse are indicated. Also, the total numbers of mice used per cell fraction are 
depicted below. C, BCR/ABLp185 leukemia consists of a homogeneous CD19+/B220+/IgM- 
cell population that infiltrates the spleen and peripheral blood of diseased mice. 
Representative FACS-plots are shown.  
 
Supplementary figure 4 | BCR/ABLp210 preserving-CSCs keep all properties of stem 
cells in vitro. 
A, Summary of FACS analysis of different surface proteins that are expressed in HSCs or in 
more mature cells. BCR/ABLp210 preserving-CSCs express all markers of HSCs and 
completely lack mature markers. B, Summary of FACS and confocal fluorescence 
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microscopy analysis of different surface proteins that are involved in HSC/niche interactions 
and homing to the bone marrow.  
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Summary   
Signals initiated by the constitutively active Bcr/Abl oncoprotein reverberate through 
a complex network involving more than a dozen pathways. The transcription factors Stat5a/b 
have previously been implicated in the initial bcr/abl-induced transformation event. However, 
to be suitable for a targeted therapy, Stat5 must be required for maintenance of leukemia 
rather than its initiation. Accordingly, we examined the effects of Stat5 deletion in either 
myeloid or lymphoid leukemia. Stat5 deletion was associated with effective elimination of 
both types of leukemic cells in vivo including leukemic stem cells. Lack of Stat5 induces 
G0/G1 cell cycle arrest and apoptosis in imatinib-sensitive and imatinib-resistant cells. Thus 
Stat5 is indispensable for the survival of a leukemic cell and a candidate alternative target for 
imatinib-resistant leukemia. 
 
Significance 
Deregulation of the Jak/Stat pathway is found in many tumors, including 
hematopoietic disorders associated with defined genetic alterations leading to the expression 
of oncoproteins (e.g. Bcr/Abl, Tel-Jak2, Jak2V617F, Flt3-ITD). Among all components of 
this pathway, in particular Stat5 was postulated a key regulator and prognostic marker.  Here 
we used bcr/abl-induced leukemia as a model to validate the suitability of Stat5 as a new 
candidate for therapy. Given that its abrogation leads to tumor cell death in both, treatment-
sensitive and treatment-insensitive leukemic cells - Stat5 is prefigured as a key player in 
tumor maintenance. Our data therefore qualify Stat5 as a suitable drug target in bcr/abl+ 
leukemia. Importantly, this absolute dependency might expand to other hematopoietic 
malignancies associated with Stat5 deregulation. 
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Introduction  
Jak (Janus kinase) and Stat (Signal transducer and activator of transcription) molecules 
are part of a highly conserved signaling pathway involved in cell fate decisions like 
differentiation, proliferation and apoptosis (Calo et al., 2003; Levy and Darnell, 2002; 
Murray, 1996). Seven members of the Stat family are known: Stat1, Stat2, Stat3, Stat4, 
Stat5a, Stat5b and Stat6 with a size ranging from 750 to 900 amino acids. Jak and Stat 
molecules are expressed in a variety of tissues mediating critical functions of cytokines and 
other signals (Levy and Darnell, 2002; Moriggl et al., 1999a; Moriggl et al., 1999b; O'Shea et 
al., 2002; Velazquez et al., 1992). The two closely related proteins Stat5a and Stat5b (here 
referred to as Stat5) have redundant functions in hematopoietic cells, and non-redundant 
functions in other tissues (Teglund et al., 1998).  
Persistent Stat5 activation is found in various types of cancer: carcinoma of breast, 
head and neck as well as hematological disorders (Bromberg, 2002; Buettner et al., 2002; 
Kornfeld et al., 2008; Yu and Jove, 2004), allowing the tumor cells to overcome their 
dependence on cytokines and growth factors. Prominent examples are myeloid and lymphoid 
malignancies associated with constitutively active forms of Jak2 (Schwaller et al., 1998; 
Tefferi and Gilliland, 2005a; Tefferi and Gilliland, 2005b; Tefferi et al., 2005; Ward et al., 
2000). In these tumors, the constitutive activation of Jak2 drives the phosphorylation and 
activation of Stat1, Stat3 and Stat5 (Ho et al., 1999; Schwaller et al., 2000). Moreover, 
constitutive activation of the Jak/Stat pathway was found in leukemic cells of patients 
suffering from bcr/abl-induced leukemia (Benekli et al., 2003; Bromberg, 2002; Lin et al., 
2000; Steelman et al., 2004). Bcr/abl-induced leukemia are characterized by a 
t(9;22)(q34;q11) translocation leading to the expression of a chimeric fusion gene product 
(Bcr/Abl) representing a constitutively active tyrosine kinase. This translocation is mainly 
linked to two distinct hematopoietic disorders: acute lymphoid leukemia (ALL) and chronic 
myelogenous leukemia (CML) (Deininger et al., 2000). There is ample evidence that Stat5 is 
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activated in bcr/abl+ cells (Carlesso et al., 1996; Chai et al., 1997; de Groot et al., 1999; Frank 
and Varticovski, 1996; Ilaria and Van Etten, 1996; Shuai et al., 1996; Spiekermann et al., 
2002). Based on experiments using dominant negative mutants of Stat5, an important role for 
Stat5 in bcr/abl-induced survival was proposed (de Groot et al., 1999; Sillaber et al., 2000). 
The importance of Stat5 for transformation of hematopoitic cells and leukemogenesis is also 
evident from the fact that transduction of bone marrow (BM) cells with a constitutively active 
mutant of Stat5 induces multi-lineage leukemia in mice (Moriggl et al., 2005). Similar results 
were obtained when long-term HSC were retrovirally transduced with constitutively active 
Stat5 mutants and transplanted. Again, a fatal myeloproliferative disease (MPD) was 
observed in the recipient mice (Kato et al., 2005). Recent evidence elucidated a diagnostic 
and prognostic role of Stat5 in human myeloproliferative disorders. Single-cell profiling 
revealed that aberrant Stat5 activation correlates with advanced stages of disease (Kotecha et 
al., 2008). 
However, initial experiments using mice expressing N-terminally deleted Stat5 
(Stat5ΔN/ΔNmice) underestimated the importance of Stat5 in bcr/abl-induced diseases since 
these animals still succumbed to leukemia (Sexl et al., 2000). Recently we clarified that Stat5 
is indeed absolutely essential for the initial transformation process mediated by v-abl and 
bcr/ablp185 oncogenes in vitro and in vivo using a complete Stat5 knockout model (Stat5null) 
(Cui et al., 2004; Hoelbl et al., 2006).  
Here, we examined whether Stat5 is also required for disease maintenance and 
qualifies as a potential alternative therapeutic target in leukemia. We show that Stat5 is a 
bottleneck in the signalling network downstream of Bcr/Abl and is unequivocally required for 
the maintenance of leukemia.  
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Results 
Bcr/ablp210- induced myeloid transformation requires Stat5  
We have previously shown that initial lymphoid transformation by the bcr/ablp185 
oncogene critically depends on Stat5 (Hoelbl et al., 2006). However the influence of Stat5 on 
chronic myeloid leukemia (CML) – associated with the bcr/ablp210 translocation form -  has 
still not been unequivocally elucidated. Therefore, we transduced fetal liver (FL) cells derived 
from Stat5+/+, Stat5null/+ and Stat5null/null embryos with a retrovirus encoding bcr/ablp210 and 
plated the cells in growth factor free methylcellulose (numbers of  bcr/abl+/GFP+ cells before 
plating: 17%, 14.8% and 28,6% respectively). As depicted in Figure 1 the number of factor-
independent Stat5null/+ colonies was drastically reduced compared to wild-type (wt) (5.4-fold). 
This reduction was even more evident for Stat5null/null FLs expressing bcr/ablp210. Here, we 
hardly observed any outgrowth of colony-like structures (28.6- fold; p< 0,0001).  These data 
indicate that Stat5 is required for the transforming capabilities of Bcr/Ablp210 in a dosage-
dependent manner. 
Next, we asked whether Stat5 is also required for the maintenance of leukemia 
progression. To induce deletion of Stat5 at any given time point, we crossed Stat5fl/fl mice 
with Mx1Cre mice. In these animals the Cre recombinase is induced by type I interferons 
(IFNs) or p(I:C) treatment. In mice, a CML-like disease is driven by a bcr/abl+c-kit+Lin- 
leukemic stem cell (LSC) population that is defined by their ability to carry on disease to  a 
secondary recipient (Krause et al., 2006; Wang and Dick, 2005). Bcr/ablp210 infected 
Stat5fl/flMx1Cre BM was transplanted into lethally irradiated wt (B6129F1) recipient mice. 
After twelve weeks, first signs of disease evolved and significant numbers of bcr/abl+/GFP+ 
cells in the peripheral blood were detected (data not shown). The mice were sacrificed and 
BMs were prepared. As depicted in Figure 2A, 13.4 + 1.3% of the BM cells were 
bcr/abl+/GFP+. Further analysis revealed that this bcr/abl+/GFP+ population consisted of 
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Mac1+Gr1+ (28.5 + 8.9%) and Lin- (25.1 ± 15.3 % ) cells being mainly stem/progenitor cells 
(Lin-c-kit+Sca-1-; 86.7 + 20.5%). 
BM cells of three diseased animals were pooled and treated ex vivo with recombinant 
IFN-β (1000U/ml) to delete Stat5 (see scheme depicted in Figure 2A). We initially planned 
to transplant a pure Stat5Δ/Δ population and to monitor CML-like disease progression in the 
secondary recipient. However, despite several efforts using various concentrations of IFN-β 
we never obtained a pure Stat5Δ/Δ population by treating bcr/abl+/GFP+ Stat5fl/flMx1Cre cells 
(Figure 2A middle panel). Thus, we reasoned that Stat5Δ/Δ cells might have a severe 
disadvantage in vitro. Hence, we decided to transplant an IFN-β treated “mixed” population 
of Stat5fl/flMx1Cre and Stat5Δ/ΔMx1Cre cells to test whether Stat5Δ/Δ LSCs are capable to 
contribute to CML in vivo (n=9). The co-transplanted non-deleted LSCs served as internal 
control for successful transplantation.  
Two weeks after the secondary transplant, recipient mice displayed clear signs of 
disease including decreased mobility and weight loss. All mice had developed leukemia with 
enlarged spleens and livers and significant numbers of bcr/abl+/GFP+ cells in the BM (Figure 
2A lower panel). We found that 45.1 + 31.5% of BM cells were bcr/abl+/GFP+. Further 
analysis revealed that these bcr/abl+/GFP+ populations were comprised of Lin- cells (20.5 ± 
7.5%) being mainly stem/progenitor cells (Lin-c-kit+Sca-1-, 91 + 5.5 %). Mac1+Gr1+ cells 
were only detected at low percentages (1.1 + 1.7%) whereas 7.2 + 4.1% of cells were 
Mac1+Gr1-. These findings indicated an accelerated stage of the disease. However, when we 
performed genotyping PCR analysis of the leukemic cells derived from BMs, we only 
detected a PCR product corresponding to the floxed Stat5 allele. The Stat5Δ allele was not 
found in any leukemic sample. Thus, the co-transplanted Stat5Δ/Δ LSCs did not contribute to 
leukemia (Figure 2A lower panel).  
 
Stat5−heterozygous cells do not induce bcr/abl+ myeloid leukemia progression 
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As shown in Figure 1, Stat5-heterozygosity had a profound effect on bcr/ablp210-
induced myeloid colony formation. This indicates that lowering Stat5 levels already impedes 
myeloid transformation. To test the effects of reduced Stat5 in bcr/ablp210-induced disease in 
vivo, we made use of Stat5fl/+Mx1Cre BM cells. At the beginning of the experiment, these 
BM cells express Stat5 from both, the wt and the floxed Stat5 allele. Equally as described 
above, we infected these cells with bcr/ablp210 and transplanted them into primary recipients. 
When the numbers of bcr/abl+/GFP+ cells in the peripheral blood increased (data not shown), 
the animals were sacrificed and BMs were prepared (n=3). The bcr/abl+/GFP+ populations 
consisted of Mac1+/Gr1+ (15.4 + 11.8%) and Lin- (22.8 ± 4.7% ) cells being mainly 
stem/progenitor cells (Lin-c-kit+Sca-1-; 82.6 + 11.7%) (Figure 2B, upper panel). BM 
preparations from three mice were pooled and the floxed Stat5 allele was deleted via IFN-ß 
treatment in vitro. In this setting a complete deletion of the remaining floxed Stat5 allele was 
achieved as verified by PCR analysis (Figure 2B, middle panel). The resulting heterozygous 
Stat5Δ/+ population, comprised of leukemic and non-leukemic cells, was then transplanted into 
secondary, lethally irradiated, recipients (n=9).   
Analysis of mice 30 days after transplantation revealed that bcr/abl+/ GFP+ cells were 
entirely missing in the BM and all other organs investigated including lymph nodes, spleen 
and liver (Figure 2B and data not shown). However, the presence of the Stat5Δ  allele was 
confirmed in the BM of the recipient animals proving successful transplantation and 
reconstitution by non-leukemic Stat5Δ/+ cells (Figure 2B, lower panel). Thus, Stat5 
heterozygous cells contribute to hematopoietic reconstitution of lethally irradiated mice but 
do not allow the outgrowth of bcr/ablp210-positive leukemic cells.   
Since Stat5Δ/+ and Stat5Δ/Δ bcr/abl+ cells did not contribute to leukemia, we next asked 
whether a p(I:C) induced loss or reduction of Stat5 would affect the survival of hematopoietic 
stem cells (HSCs) and progenitors in vivo. Therefore we induced deletion of Stat5 in adult 
healthy Stat5fl/flMx1Cre (n=3) and Stat5fl/+Mx1Cre (n=3) by p(I:C) treatment. As a control we 
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included wt Mx1Cre mice (n=4). As shown in Supplementary Figure 1 Stat5 was effectively 
and completely deleted in both, progenitors and the HSC population without reducing the 
numbers of HSCs and progenitors.  
 
Stat5 is required for lymphoid leukemia maintenance in vivo  
Our experiments with bcr/ablp210 indicate that Stat5 is not only required for the initial 
transformation of myeloid cells but also for the maintenance and progression of the disease. 
However, primary myeloid bcr/ablp210 transformed cells are not suitable for long-term 
cultivation in vitro. Hence, we used the v-abl-induced lymphoid leukemia model to further 
study the underlying effects of Stat5 loss (Rosenberg and Baltimore, 1976; Rosenberg and 
Witte, 1988; Siegler and Zajdel, 1972). V-abl+ lymphoid cell lines can be readily established 
in vitro and are applicable for long-term studies (Hoelbl et al., 2006; Kovacic et al., 2006; 
Sexl et al., 2000; Zebedin et al., 2008b). Moreover, bcr/abl-associated lymphoid disease 
represents a specific therapeutic challenge since it normally proceeds rapidly and is associated 
with a high mortality (Piccaluga et al., 2007; Pui and Jeha, 2007).   
 Stable Stat5fl/flMx1Cre and Stat5fl/fl v-abl+ lymphoid cell lines (CD19+, B220+, CD43+) 
were established and controlled for comparable proliferation rates, clone sizes in 
methylcellulose, and homing to hematopoietic organs in vivo (Supplementary Figure 2). 
To check whether cell survival of an already established lymphoid leukemia also 
depends on Stat5, we transplanted Stat5fl/flMx1Cre and Stat5fl/fl v-abl+ cell lines into Rag2-/-γc-
/- mice (n=19 and 7, respectively; 1 x 105 cells/mouse). Rag2-/-γc-/- mice lack lymphoid cells 
and are therefore particularly suited to monitor lymphoid leukemia progression. Mice that had 
received Stat5fl/flMx1Cre cells were divided into two groups (see scheme in Figure 3A). The 
first group received p(I:C) to induce type I IFN responses (n=13) to delete Stat5 in the 
leukemic cells. The second group was mock-injected with PBS (n=6). To control for effects 
of p(I:C) mice that had received Stat5fl/fl cell lines were also p(I:C) treated (n=7). P(I:C) 
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treatment was initiated seven days after the transplantation of the cells and repeated every 
four days until mice displayed signs of sickness. Starting from day 16 post transplantation, 
animals harboring leukemic cells expressing Stat5 appeared sick with decreased mobility, 
scrubby hair and weight loss. In contrast, animals harboring Stat5Δ/Δ leukemic cells appeared 
healthy with normal mobility, fur and weight. Sick animals sacrificed on day 16 and 20 
(“Stat5fl/flMx1Cre + PBS” group) were compared to healthy appearing animals where deletion 
of Stat5 was induced (“Stat5fl/fl + p(I:C)” group). In the diseased animals we found dense 
infiltrations of leukemic cells B220+CD19+ cells in spleens and BMs (Figure 3B, left 
panels). In sharp contrast, leukemic cells were hardly detectable after 16 and 20 days in mice 
where Stat5 had been deleted (Figure 3B, middle and right panels).  
Mice, where Stat5 had been deleted in the leukemic cells survived significantly longer 
(Figure 3C, mean survival of 49 days compared to 20 and 16 days in the “Stat5fl/fl + p(I:C)” 
and “Stat5fl/flMx1Cre untreated” groups, respectively). Similar results were obtained when 
immuno-competent mice were used as recipient animals (Supplementary Figure 3). 
However, finally all mice succumbed to leukemia. Examination of the leukemic cells revealed 
protein expression of Stat5 and lack of the Stat5Δ allele (Figure 3D). We reasoned that p(I:C) 
induced deletion was incomplete in vivo and that some cells escaped deletion. This scenario is 
supported by the fact that we still could induce cell cycle arrest and apoptosis in the ex-vivo 
derived leukemic cells by IFN-β treatment (Figure 3E). This rules out that the cells have 
acquired secondary mutations overcoming the Stat5-requirement.  We reasoned that an 
effective cure of the affected animals was exclusively limited by the efficiency of Cre-
recombinase-mediated gene deletion. 
 
Stat5 is essential for both, proliferation and survival of v-abl-transformed cells 
To be able to study the mechanisms how Stat5 promotes leukemia maintenance in 
vitro we used recombinant IFN-β to activate Cre-mediated Stat5 deletion. A dose of 
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1000U/ml IFN-β was able to activate Cre-recombinase without blocking cell cycle 
progression (data not shown). In contrast to IFN-β treated Stat5fl/fl cells, the resulting Stat5Δ/Δ 
cells showed instantaneous proliferation arrest (Figure 4A) and no viable cells were 
detectable nine days after the initial IFN-β treatment. Genotyping PCR analysis confirmed 
efficient deletion of Stat5 (Figure 4B). To characterize the effects of Stat5 deletion, cell cycle 
profiles and apoptosis stains after IFN-β treatment were performed. As depicted in Figure 4C 
Stat5Δ/Δ cells underwent a G0/G1 cell cycle arrest two days after IFN-β treatment (67.7% + 
1.7% within G0/G1 phase). This cell cycle arrest was followed by apoptosis: nine days after 
the initiation of the experiment, 90.5% + 0.7% of Stat5Δ/Δ but only 13.1% + 2.1% of Stat5fl/fl 
cells treated with IFN-β were  propidium iodide (PI)-positive (Figure 4D).  
 
The re-expression of wt Stat5 rescues survival and proliferation  
To verify that the observed effects are indeed solely provoked by the loss of Stat5 we 
introduced a retroviral construct encoding Stat5 into yet undeleted Stat5fl/flMx1Cre cell lines. 
(Moriggl et al., 1999b). As depicted in Figure 5A, the expression of wt Stat5, but not of the 
empty vector was capable to prevent cell death after nine days upon deletion of endogenous 
Stat5 via IFN-β in vitro. PCR analysis confirmed complete deletion of the endogenous Stat5 
alleles. Additionally, we examined two Stat5 variants. Stat5Δ749 is described to exert dominant 
negative effects by blocking the DNA-binding site of Stat5 target genes (Moriggl et al., 
1996). Stat5Y694F was reported to prevent homodimerization – a prerequisite for nuclear 
translocation and transcriptional activity of Stat5 (Gouilleux et al., 1994; Stoecklin et al., 
1997; Yamashita et al., 1998). Expression of both Stat5 mutants failed to rescue the apoptotic 
effect of endogenous Stat5 loss after IFN-β treatment (Figure 5B). Accordingly, 48 hours 
after IFN-β treatment, we observed down-regulations of several well-described Stat5 target 
genes such as pim-1, cyclin D3, bcl-XL, CIS, cyclin D2 and c-myc (Figure 5C) (Castro et al., 
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1999; Dumon et al., 1999; Lord et al., 2000; Martino et al., 2001; Matsumoto et al., 1997; 
Moon et al., 2004; Peltola et al., 2004; Socolovsky et al., 1999; Stout et al., 2004; Yoshimura 
et al., 1995). To test whether a single target gene compensates for the loss of Stat5 upon IFN-
β administration, we over-expressed either CIS, c-myc, cyclin D2, cyclin D3 or bcl-XL. As 
depicted in Figure 5D, expression of neither of these Stat5 target genes was capable to 
compensate for the loss of Stat5. Therefore, not a single Stat5 target gene, but rather Stat5 as 
a superordinate molecule, maintains the leukemic capacity of bcr/abl+ cells.   
 
High Bcl2 levels or deletion of Trp53 do not relieve Stat5-dependance  
Tumor cells frequently acquire additional mutations after long term maintenance in 
culture. We therefore analyzed our Stat5fl/fl Mx1Cre cell lines after 14 months of continuous 
culture whether any spontaneously acquired mutation would be capable to release the 
necessity for Stat5. When we analyzed the cell lines for expressions of Trp53, BclXL and Bcl2, 
we found that two cell lines (#1 and #3) had completely lost the Trp53 protein (Figure 6A). 
Loss of Trp53 was reported to result in a decreased sensitivity towards imatinib (Wendel et 
al., 2006). Accordingly these cell lines displayed a 5.7-fold lesser sensitivity towards imatinib 
treatment (IC50 of 0.98 µM compared to IC50=0.17 µM; data not shown). Cell line #1 
additionally displayed a significant up-regulation of the Bcl2 protein and a significant 
decrease in Stat5 protein expression. Bcl2 is an anti-apoptotic protein, whose over-expression 
is found in many cancers contributing to tumor initiation, progression and resistance to 
therapies (Danial and Korsmeyer, 2004; Letai et al., 2004; Oltersdorf et al., 2005). However, 
when the residual Stat5 protein was removed by activation of Cre-recombinase, all cell lines 
still underwent complete apoptosis. Hence, even in the presence of elevated Bcl2 protein the 
presence of Stat5 was indispensable for proliferation and survival of leukemic cells. This is in 
line with our observations that over-expression of Bcl2 in Stat5fl/flMx1Cre cell lines and 
subsequent deletion of endogenous Stat5 does not release Stat5 dependence. (Figure 5D).   
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Expression of an imatinib-resistant bcr/abl mutant (bcr/ablp210T315I) does not relieve Stat5 
dependance 
Treatment of bcr/abl-induced CML has been significantly improved by the availability 
of imatinib (Druker et al., 2001a; Druker et al., 2001b). However, some patients acquire 
mutations in the Bcr/Abl oncoprotein which renders them insensitive to imatinib (Chu et al., 
2005; Griswold et al., 2006). In this regard the bcr/ablp210T315I mutation represents one of the 
biggest therapeutic challenges in CML therapy since it mediates complete resistance not only 
to imatinib but also to all of the next generation Abl kinase inhibitors (Quintas-Cardama et al., 
2007; Skaggs et al., 2006). We therefore decided to test whether cells expressing 
bcr/ablp210T315I require the presence of Stat5. Stat5fl/flMx1Cre and Stat5+/+Mx1Cre BM cells 
were infected with retrovirus encoding bcr/ablp210T315I and treated either with imatinib or IFN-
β-mediated Stat5 deletion.  
To ensure survival and proliferation of immature progenitors, cells were maintained in 
a medium supplemented with SCF, Flt3-ligand (Flt3-L), IgF-1, IL-3, IL-6 GM-SCF and 
dexamethasone as described previously (Kieslinger et al., 2000). As expected wt Mx1Cre and 
Stat5fl/flMx1Cre cells expressing bcr/ablp210T315I did not undergo apoptosis upon imatinib 
treatment (Figure 6B, middle panels). In contrast, bcr/ablp210T315I expressing Stat5fl/flMx1Cre 
cells showed substantial cell death upon loss of Stat5 after five days (Figure 6B, right 
panels).     
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Discussion 
A major issue in cancer biology is to differentiate between initiating events and events 
that are required for cancer progression. While substantial progress has been made in 
understanding the evolution of solid tumors, the evolution of leukemic cells is less well 
understood (Albertson et al., 2003; Klein and Klein, 1985; Lengauer et al., 1998; Nowell, 
1976; Visvader and Lindeman, 2008). In this regard, Bcr/abl-induced leukemia is a good 
model system because the initiating event is a well-defined chromosomal translocation (Ren, 
2005; Wong and Witte, 2001). Previously, we showed that Stat5 is required for the initiation 
of lymphoid leukemia (Hoelbl et al., 2006). In this manuscript we provide formal proof for an 
essential role of Stat5 in the maintenance of bcr/abl+ leukemia. Deletion of Stat5 in leukemic 
cells resulted in G0/G1 cell cycle arrest followed by apoptosis. To the best of our knowledge 
this is the first report where an indispensable and non-redundant function of a signaling 
component downstream of the Bcr/Abl tyrosine kinase is described to be necessary for 
leukemia progression in vivo. Several signaling pathways are activated downstream of the 
Bcr/Abl oncoprotein and are implied to contribute to leukemogenesis, e.g. the activation of 
the Phosphatidylinositol 3-kinase (PI3K) pathway or the mitogen-activated protein (MAP) 
kinase pathway (Cortez et al., 1997; Deininger et al., 2000; Ren, 2005; Wong and Witte, 
2004; Zebedin et al., 2008a).                                                                                                                                                                                                   
In this complex signaling network, controlled by Bcr/Abl, Stat5 appears to have a 
unique and privileged position: in fact, our experiments verify that Stat5 is the bottleneck for 
both, bcr/abl-induced disease initiation and progression. The unique role of Stat5 is conserved 
even in the absence of intact Trp53 signaling, as well as in imatinib-resistant cells and most 
importantly extends to the leukemic stem cell (LSC) compartment.   
These findings single out Stat5 from other members of the family of Stat transcription 
factors that have been implicated in signaling downstream of Bcr/Abl. Stat3 is also involved 
in the initial transformation process which is severely impaired in the absence of Stat3. 
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However, Stat3 is dispensable for leukemia progression (V. Sexl, unpublished observations). 
Importantly, the requirement for Stat5 extends to the LSC compartment. LSCs have been 
characterized in myeloid bcr/ablp210-induced leukemia by their ability to allow for serial 
transplantation of the disease (Krause et al., 2006; Wang and Dick, 2005). One of the big 
current therapeutic challenges is to find strategies how to target and eradicate such LSCs. The 
most frequently used drug in CML therapy - imatinib - induces apoptosis in bcr/abl+ cells but 
fails to eradicate LSCs in vivo (Krause and Van Etten, 2007; Neering et al., 2007). Therefore, 
patients must be subjected to continuous treatment to keep them in remission. This situation 
fosters Darwinian evolution and the emergence of resistant clones. In this context, it is worth 
pointing out that even one of the most dreaded imatinib-resistant mutants of Bcr/Abl - 
Bcr/Ablp210T315I – remains strictly dependent on Stat5.  Taken together, these observations 
support the concept that targeting Stat5 provides new therapeutic opportunities. This 
conjecture is further supported by the observation that the mere lowering of Stat5 levels in 
bcr/ablp210+ Stat5fl/+Mx1Cre cells by IFN-β treatment was sufficient to prevent leukemia 
progression in secondary recipient animals - again pointing at the role of Stat5 in LSCs. In 
these animals, the non-leukemic Stat5Δ/+ cells contributed to normal hematopoiesis. This 
indicates that a reduced Stat5 protein level may be well tolerated in normal tissue but is 
deleterious for the bcr/abl+ cell population. It also indicates that partial blockage of Stat5 may 
be tolerated, despite its described role in HSC functionality and hematopoiesis (Wierenga et 
al., 2008). While it is difficult to extrapolate these experiments in mice to patients, at the very 
least these observations justify the assumption that potential side effects of Stat5 blockage 
will not a priori preclude their use in clinics. This conjecture is further supported by the 
development of an inhibitor targeting Jak2. Jak2 is essential for erythropoiesis - but 
nevertheless, Jak2 inhibitors have successfully entered clinical trials (Hexner et al., 2008; 
Lasho et al., 2008; Wernig et al., 2008). 
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For the past decade, signal interceptor-based therapies have been the most promising 
new strategies in the treatment of cancer. Stat5 fulfills two important criteria as a drug target 
for a signal interceptor: (i) Stat5 is a valid target in bcr/abl-induced leukemia because it is 
essential for the disease; (ii) blockage of Stat5 can be anticipated to result in limited and 
tolerable side effects. (iii) Stat5 occupies a privileged position in the Bcr/Abl signaling 
network. This is also evident from microarray data showing that Stat5 target genes are 
prominently down-regulated in response to the Bcr/Abl kinase inhibitor dasatinib (O. 
Hantschel, paper in press). 
However, we found that none of the downstream targets of Stat5 are capable of 
compensating for Stat5 loss in leukemic cells when over-expressed. Similarly, our 
observations are consistent with the interpretation that the function of Stat5 cannot be readily 
bypassed: down-regulation of Stat5 significantly impaired the expression of target genes that 
can also be addressed via alternative routes in the Bcr/Abl-controlled network: e.g. D-type 
cyclins or c-myc via the MAPK/ERK cascade (Marampon et al., 2006; Okabe et al., 2006; 
Serra et al., 2008; Vadiveloo et al., 1998). These findings again highlight that Stat5 is the 
Achilles' heel of the bcr/abl- transformed cell. Importantly, we observed that even the genetic 
instability associated with the abrogation of the Trp53 did not allow for the emergence of 
Stat5-independent leukemic clones.  
Last but not least, we found that the requirement for Stat5 for cell survival was not 
relieved by forced expression of Bcl2 or BclXL. This data were confirmed by a spontaneous 
mutation occurring in one cell line that displayed high protein levels of Bcl2. This cell line 
still underwent apoptosis upon Stat5 abrogation. 
Apart from regulating transcription, Tyr694-phosphorylated Stat5 has recently been 
shown to function as a scaffold for Gab2/PI3K thereby promoting PI3K signaling (Nyga et 
al., 2005). Copious amounts of Stat5 are present in the cytoplasma of CML cells (Harir et al., 
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2007). It is therefore attractive to speculate that this mechanism might also contribute to the 
effects of Stat5 within the Bcr/Abl signaling network.  
Taken together our observations argue for a privileged position of Stat5 in the 
signaling network controlled by Bcr/Abl. Stat5 appears to be the bottleneck through which 
signals must be funneled in an obligatory and non-.redundant way. 
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Experimental procedures 
Mice and genotyping 
 
 Stat5fl/flMx1Cre, Stat5fl/fl, C57BL/6J and Rag2-/γc-/- mice were maintained at the 
Biomedical Research Institute (Medical University of Vienna), C57BL/6J x Sv129 F1 (here 
referred to as B6129F1), at the Institute of Molecular Pathology (IMP, Vienna) under 
specifically pathogen-free sterile conditions. Genotyping of mice and cells was performed as 
described previously (Cui et al., 2004). All animal experiments were carried out in accordance 
with protocols approved by Austrian law.  
BM transplants of bcr/abl p210 infected cells  
 
BM cells from 6 weeks old Stat5fl/flMx1Cre and Stat5f/+Mx1Cre donor mice were co-
cultivated on bcr/ablp210 retroviral producer cells for 48 hours in the presence of IL-3 
(25 ng/ml), IL-6 (50 ng/ml), SCF (50 ng/ml) and 7 µg/ml polybrene. Then, cells were 
transplanted via tail vein injection into lethally irradiated (10 Gy) B6129F1 recipient mice. 
Peripheral blood was taken every week and upon detection of bcr/abl+/GFP+ cells, mice were 
sacrificed. BM cells of three diseased animals were pooled and treated with recombinant IFN-
ß (1000U/ml; Serotech) for 48 hours to delete Stat5. Thereafter cells were transplanted into 
lethally irradiated secondary recipients (B6129F1). 
Deletion of Stat5 in leukemic cell lines 
 
For in vivo deletion of Stat5, 1 x 105 or 1 x 106 v-abl+ Stat5fl/fl and Stat5fl/flMx1Cre 
cells  were injected via the tail vein into Rag2-/-γc-/- or C57BL/6J mice, respectively. From day 
seven on, mice received 400µg p(I:C) (Sigma) intraperitoneally (i.p.) every four days to 
induce Stat5 deletion in the transplanted leukemic cells. Mice, injected with PBS served as 
controls. Upon signs of sickness (decreased mobility, weight loss and scrubby fur), mice were 
sacrificed and lymphatic organs were analyzed for leukemic cell (CD19+, B220+) infiltration 
by flow cytometry. 
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For in vitro deletion of Stat5, Stat5fl/flMxCre v-abl+ cell lines were seeded at a density 
of 3 x 105 cells/ml and incubated for 48 hours in 1000U/ml recombinant (IFN-ß; Serotech) in 
complete RPMI. Stat5fl/fl cell lines treated with IFN-ß and Stat5fl/flMxCre without any 
treatment served as controls. Cells were analyzed by flow cytometric analysis for cell cycle 
progression and apoptosis every day. 
Flow cytometry  
For analysis of leukemic cell lines or ex-vivo derived cells, single cell suspensions 
were pre-incubated with αCD16/CD32 antibodies to prevent non-specific Fc-receptor-
mediated binding. Subsequently, 5 x 105 cells were stained with monoclonal antibodies 
conjugated with fluorescent markers and analyzed by a FACSCantoII flow cytometer using 
FACSDiva software (Becton-Dickinson). The following antibodies, all purchased from BD 
Biosciences, were used: B220 (RA3-6B2), CD19 (1D3), CD43 (1B11), Mac-1 (M1/70), GR-1 
(RB6-8C5), mouse-lineage panel and Sca-1 (D7). C-kit (2B8) was purchased from 
eBioscience. 
Cell cycle and apoptosis analysis: 1 x 106 cells were stained with PI (50 µg/ml) in a 
hypotonic lysis solution (0.1% sodium citrate, 0.1% triton X-100, 100 µg/ml RNAse) and 
incubated at 37°C for 30 minutes. Analysis of dead/ late apoptotic cells was performed by re-
suspending in PBS containing PI (1µg/ml).  
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Figure legends  
Figure 1. bcr/ablp210-induced transformation depends on Stat5 in vitro.  
Bcr/ablp210- induced colony formation of Stat5+/+, Stat5null/+ and Stat5null/null FL cells in 
growth-factor free methylcellulose (n=3 for each genotype). One representative set of data is 
depicted. Data are summarized in a bar graph (right panel). 
Figure 2.  bcr/ablp210-induced disease progression depends on Stat5 in vivo. 
Stat5fl/flMx1Cre (A) or Stat5fl/+Mx1Cre (B) were used as donor mice. As depicted in schemes 
(left panel each) BM cells were infected with bcr/ablp210and transplanted into lethally 
irradiated recipient mice (“1st tp”). After 12 weeks, BM cells were isolated, pooled (n=3), 
treated with IFN-ß for 48h in vitro to induce deletion of the Stat5 alleles and injected into 
secondary lethally irradiated recipients (“2nd tp”; n=9 per genotype). Middle panels in (A) and 
(B) show PCR analysis of BMs at indicated steps of the experiments. Right panels in (A) and 
(B) depict flow cytometric analysis of BMs cells after 1st tp and 2nd tp as indicated. (A) PCR 
analysis revealed that only leukemic cells harbouring the floxed (fl), but no deleted (Δ) Stat5 
alleles contributed to leukemia. (B) No bcr/abl+/GFP+ cells were detected in BM cells of 
secondary recipients. PCR analysis of the non-leukemic BM verified successful 
transplantation (two representative samples are shown). One representative flow cytometric 
profile of BM cells is depicted for each experimental group. Numbers indicate percentages of 
cells belonging to individual sub-populations.  
Figure 3. Lymphoid leukemia progression depends on Stat5 in vivo. 
(A) V-abl+ Stat5fl/flMx1Cre cells were injected into Rag2-/-γc-/- mice and divided in two 
groups: one receiving p(I:C)- the other receiving PBS-injections (control).  
(B) BM and spleen of p(I:C) - treated and control mice were analyzed at indicated time points 
for the presence of transplanted leukemic B-cells (B220+CD19+). Representative flow 
cytometric profiles are depicted. 
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(C) Transplantation of Stat5fl/flMx1Cre and Stat5fl/fl cell lines into Rag2-/-γc-/- mice. 1 x 105 
cells of Stat5fl/flMx1Cre or Stat5fl/fl cell lines (n=3 each) were injected via tail vein. From day 
7 on, 400µg p(I:C) was injected i.p. every 4 days till the mice diseased. Kaplan-Maier plots 
revealed a statistically significant difference in survival time of mice after Stat5 deletion 
compared to the control groups (“Stat5fl/flMx1Cre + p(I:C)” vs. “Stat5fl/flMx1Cre untreated” 
p<0.001; “Stat5fl/flMx1Cre untreated” vs. Stat5fl/fl + p(I:C)” n.s.). Vertical bars indicate mice 
opened as controls on day 16 and 20 (see (B)).  
(D) Analysis of ex vivo derived BM cells from mice of the “Stat5fl/flMx1Cre + p(I:C”  group 
sacrificed on day 56 (#1-3) and 57 (#4). Western Blot for Stat5 (upper panel) and 
corresponding genotyping PCR analysis (lower panel). Four representative samples are 
shown. 
(E) Ex-vivo derived cells are still sensitive to the loss of Stat5. 0.5 x 105 ex-vivo-derived 
Stat5fl/flMx1Cre cells (n=3) were incubated with 1000U/ml IFN-ß. Cell concentrations were 
determined per trypane-blue exclusion on indicated time points.  
Figure 4.  Leukemic cell survival depends on Stat5 in vitro. 
(A) 0.5x105 cells of indicated cell lines (n=3 each) were treated with 1000U IFN-β or mock 
treated. Cell concentrations were determined by trypane-blue exclusion assay on indicated 
time points.  
(B) PCR analysis after IFN-β treatment: Deletion efficiency was determined by specific PCR 
reaction for the floxed (fl) and deleted (Δ) Stat5 alleles 48 hours after IFN-ß treatment.  
Cell cycle (C) and apoptosis (D) analysis of IFN-β treated v-abl transformed cell lines, 
48hours and 9 days after IFN-β treatment, respectively. Loss of Stat5 induces cell cycle arrest 
and apoptosis. Numbers show percentages of cells in indicated cell cycle phases (C) or in late 
apoptosis (D) of one representative sample for each genotype. 
Figure 5. Stat5 re-expression rescues effects of Stat5 deficiency 
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Stat5fl/flMx1Cre cell lines were infected with retroviruses encoding either empty vector, wt 
Stat5 (A), Stat5Y694F and Stat5Δ749 (B) or indicated Stat5 target genes (D). (A) Percentages 
of late apoptotic/dead cells, were determined nine days after IFN-β administration by PI 
staining. PCR analysis revealed complete deletion of Stat5-re-expressing cells.  Numbers 
indicate percentages of PI+ cells. 
 (C) 48 hours after IFN-β administration, expression levels of Stat5 target genes were 
analyzed by real-time PCR and compared to levels measured in equally treated Stat5fl/fl cells. 
Down-regulations of indicated target genes are summarized in bar graphs. Data represent 
means + SD. Asteriks indicate statistical significance as determined by a one-sample T-test 
(two-tailed; *** p<0.001). 
(B, D) Endogenous Stat5 was deleted via IFN-β and outgrowth of GFP+ cells was monitored 
by flow cytometry every 48 hours for eight subsequent days. 
Figure 6. Leukemic cells harbouring second hits are still sensitive to Stat5 loss. 
(A) Long term cultured (14 months) Stat5fl/flMx1Cre v-abl+ cell lines were examined by 
Western blot analysis for Stat5, Trp53, Bcl2 and BclXL protein expressions. Two cell lines 
either over-expressing Bcl-2 and/or lacking Trp53 (# 1, #3) were subjected to Stat5 deletion 
via IFN-β. Cell cycle progression was analyzed by PI staining and FACS analysis after 48 
hours. Percentages of apoptotic cells were determined via PI staining nine days after IFN-β 
administration. Numbers show percentages of cells in indicated cell cycle phases (middle 
panel) or in late apoptosis (right panel). 
(B) BMs of wt Mx1Cre and Stat5fl/flMx1Cre mice were infected with an imatinib-resistant 
bcr/ablp210 mutant (bcr/ablp210T315I) and treated with either imatinib (0.1µM) or IFN-β. After 5 
days cells of the IFN-ß-treated, but not of the imatinib-treated group, showed increased 
numbers of apoptotic (sub-G1) cells. Numbers show percentages of cells in indicated cell 
cycle phases. 
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Figure S1. Effect of Stat5 deletion on normal HSCs and progenitors. 
(A) HSCs and progenitors from bone marrows of Stat5fl/flMx1Cre and Stat5fl/+Mx1Cre mice (6 
weeks of age) were FACS-sorted after p(I:C) treatment (two times, 300µg i.p.). Deletion 
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efficiency was analyzed by PCR reactions specific for floxed (fl) or deleted (Δ) Stat5 alleles. 
Numbers indicate samples from individual mice. 
(B) FACS analysis of HSC and progenitor populations in wt Mx1Cre, Stat5fl/flMx1Cre and 
Stat5fl/+Mx1Cre mice after p(I:C) treatment. Lin- BM cells were gated and analyzed for c-kit 
and Sca-1 surface expression. Bar graphs summarize quantifications of Lin-c-kit+Sca-1+ 
(HSCs) and Lin-c-kit+Sca-1- cells. Data represent means + SD. 
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Figure S2. Stat5fl/flMx1Cre and Stat5fl/fl v-abl+ cell lines proliferate comparably in vitro 
and in vivo. 
(A) 3[H] thymidine incorporation of Stat5fl/flMx1Cre and Stat5fl/fl cell lines. Data represent 
means of three individual cell lines per genotype + SD. The experiment was performed in 
triplicates. 
(B) Colony formation of stable Stat5fl/flMx1Cre and Stat5fl/fl v-abl+ cell lines (n=3 each.) 1 x 
103 cells were plated in growth factor free methylcellulose. After seven days no differences in 
clone size were evident (magnification 4x, 40x). One representative data set is shown. 
(C) Homing of Stat5fl/flMx1Cre and Stat5fl/fl cell lines in vivo. 1 x 106 CSFE labelled cells 
were i.v. injected into Rag2-/-γc-/- mice (n=3). After 24 hours the mice were sacrificed and 
BMs and spleens were analysed by FACS. One representative data set is shown. 
 99 
 
Figure S3. Transplantation of Stat5fl/flMx1Cre and Stat5fl/fl v-abl+ cell lines into wt 
C57BL/6J mice.  
1 x 106 cells of Stat5fl/flMx1Cre or Stat5fl/fl cell lines (n=3 each) were injected via the tail vein. 
From day seven on, 400µg p(I:C) was injected i.p. every four days until mice diseased. 
Kaplan-Meier analysis revealed a significant difference in survival time of mice after Stat5 
deletion compared to control group (“Stat5fl/flMx1Cre + p(I:C)” vs. “Stat5fl/flMx1Cre 
untreated” p<0.001; “Stat5fl/flMx1Cre untreated” vs. Stat5fl/fl + p(I:C)” n.s.). Mice of the 
(“Stat5fl/flMx1Cre + p(I:C)” group displayed a mean survival of 23.3 days, whereas mice of 
“Stat5fl/flMx1Cre untreated” and “Stat5fl/fl + p(I:C)” groups survived on average 15.4 and 16.5 
days, respectively. 
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Supplemental Experimental Procedures 
Retroviral constructs 
Stat5 target genes, Stat5 mutants and bcr/ablp210 were cloned into a pMSCV-IRES-GFP, 
Bcr/Ablp210T315I into a pMSCV-IRES-dsRed backbone.  
Tissue culture conditions and virus preparation 
  
Transformed FL cells and tumor-derived cell lines were maintained in RPMI 1640 
medium containing 10% fetal calf serum (FCS), 100U/ml penicillin/streptomycin, 50 µM β-
mercaptoethanol and 2 mM L-glutamine (“RPMI complete”). A010 and gp+E86 cells were 
maintained in DMEM medium containing 10% fetal calf serum (FCS), 100U/ml 
penicillin/streptomycin, 50 µM β-mercaptoethanol and 2 mM L-glutamine (“DMEM 
complete”). Cell culture media were purchased from Sigma. Standard supplements were 
purchased from Gibco. 
A010 cells produce an ecotropic replication deficient form of the Abelson murine 
leukemia virus (A-MuLV) encoding the v-abl oncogene and were a generous gift of Dr. 
Naomi Rosenberg. Gp+E86 retroviral packaging cell lines for Stat5 target genes, bcr/ablp210 
as well as mutated version thereof (bcr/ablp210T315I) were established by transfection 
(Lipofectamine Invitrogen®). Cells were sorted for expression of fluorescent proteins using 
BD FACS-Vantage device.  
Bcr/ablp210 and bcr/ablp210T315I infected BM cells were maintained in Stem Cell Pro 
medium supplemented with mSCF (50ng/ml), murine IL-3 (2ng/ml), Flt3-L (10ng/ml), 
murine GMCSF (3ng/ml), IGF-1 (40ng/ml), dexamethasone (1µg/ml) and mouse IL-6 (0,5 
ng/ml) (all purchased from R&D Systems) (“stem cell medium”) as described before 
(Kieslinger et al., 2000). 
Infections and establishment of cell lines  
 
For the preparation of lymphoid cell lines, Stat5fl/fl and Stat5fl/flMx1Cre animals were 
set up for breeding. Fourteen days after conception pregnant animals were sacrificed and FLs 
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prepared. Single cell suspensions from FLs were infected for one hour with viral supernatant 
derived from A010 cells in the presence of 7 µg/ml polybrene as described previously (Sexl et 
al., 2000). The cells were then maintained in complete RPMI medium and observed for the 
outgrowth of stable transformed cell lines.  
In vitro colony formation assay  
Single cell suspensions from FLs (ED 13.5) were co-cultivated on bcr/abl p210 
producer cells in the presence of IL-3 (25 ng/mL), IL-6 (50 ng/mL), SCF (50 ng/mL) and 7 
µg/ml polybrene for 48 hours as described previously (Sexl et al., 2000). After infection, 1 x 
104 GFP+ cells were resuspended in 3 ml cytokine-free methylcellulose (Stem Cell 
Technologies) and plated in 35 mm dishes (1.5ml each). After five days, colonies were 
counted by light microscopy (Leica Fluovert microscope, 4 x magnification).  Images of cell 
culture dishes were scanned using a standard on-desk scanner. 
For comparison of growth capacity between Stat5fl/flMx1Cre and Stat5fl/fl v-abl+ stable 
lymphoid cell lines, 1 x 103 cells were plated in cytokine-free methylcellulose and evaluated 
as described above.  
Re-expression of wt Stat5 and Stat5 target genes in stable v-abl+ cell lines and rescue 
assays 
Infections with indicated Stat5 target genes were performed using retroviral producer 
cell lines as described above. Thereafter GFP+ cells were sorted using a FACSAria (Becton 
Dickinson) and pure GFP+ cell lines were mixed with non-transfected ones of the same 
genotype at a ratio of 1:33. To determine rescue capacity of indicated target genes cells were 
treated with 1000U/ml recombinant IFN-β for 48 hours. Thereafter the percentage of GFP+ 
cells was determined daily by flow cytometry. 
 
CSFE in vivo proliferation assay 
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Cells were labelled with CFSE (carboxy-fluorescein diacetate, succinimidyl ester; Sigma) at a 
final concentration of 0,5 µM in PBS. Subsequently, 1 x 106 cells were injected via the tail 
vein into Rag2-/-γc-/- recipient mice. 24 hours after injection, mice were sacrificed and BMs 
and spleens were analyzed by flow cytometry for the presence of labelled cells. In vitro 
maintained cells served as control. 
[3H] thymidine incorporation 
 
Cells were plated at a density of 2 x 105 cells in 96 round bottom wells. 0.1 µCi [3H] 
thymidine/well (PerkinElmer). After 24 hours, cells were frozen at -80°C, re-thawn and then 
analyzed using a Skatron semi-automatic cell harvester. Incorporation of [3H] thymidine was 
measured by a Packard scintillation counter upon addition of scintillation fluid (Rotiszint 
ECO plus, Roth GmbH & Co KG).  
Cell extracts and Western blotting 
 
Cells were lysed in a buffer containing protease and phosphatase inhibitors (50 mM 
Hepes, pH 7.5, 0.1% Tween-20, 150 mM NaCl, 1 mM EDTA, 20 mM β-glycero-phosphate, 
0.1 mM sodium vanadate, 1 mM sodium fluoride, 10 µg/ml aprotinin, leupeptin and 1 mM 
PMSF, respectively). Protein concentrations were determined using a BCA-kit (Pierce, 
Rockford, IL).  
Proteins (50-100 µg) were separated on an 8% SDS polyacrylamide gel and 
transferred onto Immobilon membranes. Membranes were probed with antibodies directed 
against Stat5, Trp53, Bcl2, BclXL, β-actin and holo-ERK (all purchased from Santa Cruz 
Biotechnologies). Immunoreactive bands were visualized by chemoluminiscent detection 
(ECL detection kit; Amersham, Arlington Heights, UK) using protein A-conjugated 
horseradish peroxidase (Amersham, Arlington Heights, UK). 
Real-time PCR analysis 
 
RNA was isolated using TriZol (Invitrogen). RNA integrity was checked with the 
Agilent Bioanalyzer (Agilent). 2.5 µg RNA was reverse transcribed using Superscript II 
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reverse transcriptase (Invitrogen). Real time PCR was performed on an Eppendorf RealPlex 
cycler using RealMasterMix (Eppendorf) and SYBR Green as described before (Kerenyi et 
al., 2008). The following primer pairs were used: 
pim-1 5´ACGTGGAGAAGGACCCGATTTCC 3´ and 3´GATGTTTTCGTCCTTGATGTCGC 3´ 
cis 5´CTGCTGTGCATAGCCAAGACGTTC 3´ and 5´CAGAGTTGGAAGGGGTACTGTCGG 3´ 
cyclin D2, 5’ AGA AGG GGC TAG CAG ATG A 3’ and 5’ AGG ATG ATG AAG TGA ACA CA-
3’ 
cyclin D3 5´TGCATCTATACGGACCAGGCT 3´and 5´AGGAAGTCGTGCGCAATCA 3´  
bclXL  5 TTGGATGGCCACCTATCTGAAT 3´and 5´TCTCGGCTGCTGCATTGTT 3´  
hypoxanthine-guanine phosphoribosyltransferase (control) 
hprt 5’ TGA TTA GCG ATG ATG AAC CAG G 3’ and 5’ CCT TCA TGA CAT CTC GAG CAA G 
3’ 
In vitro imatinib sensibility assay of bcr/ablp210T315I- transformed cells 
 
BM cells from 6 weeks old Stat5fl/flMx1Cre and Stat5+/+ Mx1Cre mice were co-cultivated 
with viral producer cells encoding a imatinib-resistant version of bcr/ablp210 (bcr/ablp210T315I) 
as described above. After 48 hours of infection cells were maintained in stem cell medium as 
described above and treated either with 100 nM Imatinib or 1000U/ml recombinant IFN-ß. 
Cells were analyzed by flow cytometry for cell cycle distribution daily. 
Statistical analysis 
Statistics were carried out using Student´s t-test, Mann-Whitney-test or a one-way 
ANOVA test as appropriate. Differences in Kaplan-Meier plots were analyzed for statistical 
significance using the log-rank test. Data are presented as averages ± SD and were analyzed 
by Graph Pad® and SPSS software. 
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Boris Kovacic1,4, Dagmar Stoiber1,2, Richard Moriggl2, Eva Weisz1, Rene G. Ott1, Rita 
Kreibich1, David E. Levy3, Hartmut Beug4, Michael Freissmuth1 and Veronika Sexl1 
 
1Department of Pharmacology, Medical University of Vienna (MUW), Vienna A-1090, 
Austria 
2Ludwig Boltzmann Institute for Cancer Research (LBI-CR), Vienna A-1090, Austria 
3Department of Pathology and Microbiology, New York University School of Medicine, New 
York 10016 
4Institute of Molecular Pathology (IMP), Vienna A-1030, Austria 
 
 
 157 
 158 
 159 
 160 
 161 
 162 
 163 
 164 
 165 
 166 
 167 
 168 
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